

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>C12P 19/28, 1/00, 19/18</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/21038</b> <b>(43) International Publication Date:</b> 11 July 1996 (11.07.96)
<b>(21) International Application Number:</b> PCT/FI96/00002 <b>(22) International Filing Date:</b> 2 January 1996 (02.01.96)  <b>(30) Priority Data:</b> 08/366,800 30 December 1994 (30.12.94) US  <b>(71) Applicant (for all designated States except US):</b> ALKO GROUP LTD. [FI/FI]; Salmisaarenranta 7, FIN-00180 Helsinki (FI).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> MARAS, Marleen [BE/BE]; Sasstraat, B-9050 Gentbrugge (BE). CONTRERAS, Roland [BE/BE]; Molenstraat 53, B-9820 Merelbeke (BE).  <b>(74) Agent:</b> OY BORENIUS & CO. AB; Arkadiankatu 21 A, FIN-00100 Helsinki (FI).	<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>	
<b>(54) Title:</b> METHODS OF MODIFYING CARBOHYDRATE MOIETIES  <b>(57) Abstract</b>  The invention is directed to methods of converting high mannose type glycosylation patterns to hybrid or complex type glycosylation patterns.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CJ	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## Methods Of Modifying Carbohydrate Moieties

### *Field of the Invention*

The invention is directed to a method for converting glycosylation patterns on proteins and cells to a hybrid or complex pattern. This is especially useful for recombinantly-produced, therapeutic proteins that are to be administered to a mammalian, especially human, patient.

### *Background of the Invention*

Glycosylation affects many properties of a glycoprotein, including proper protein folding, protease resistance/sensitivity, intracellular trafficking and compartmentalization, secretion, inter- and intra-molecular associations, intermolecular affinities, tissue targeting and biological half-life. Glycosylation patterns may also significantly alter the biological activity, solubility, clearance, intermolecular aggregation and antigenicity, especially of those proteins that are administered therapeutically *in vivo*.

Unfortunately, the recombinant production of many proteins can greatly alter their glycosylation pattern. Proteins expressed in bacteria are completely unglycosylated. Baker's yeast glycosylation patterns are not equivalent to mammalian counterparts and are highly antigenic in mammals (Ballou, C.E., 1982. *In* Strathern, J.N. *et al.* (eds). *The Molecular Biology of the Yeast Saccharomyces. Metabolism and Gene Expression*. Cold Spring Harbor Laboratory Press, New York, pp. 335-360).

Similarly, non-complex glycosyl moieties are observed when insect cells, such as the popular Sf9 baculovirus expression system, are used to express mammalian proteins (Davidson *et al.*, *Biochemistry*, 29:2828-2838 (1990); Bahl, O.P. *et al.*, in *Cell Surface and Extracellular Glycoconjugates - Structure and Function*, D.D. Roberts *et al.*, eds., Academic Press, Inc. 1993 pp. 245-270). High mannose (Man) and hybrid oligosaccharides are synthesized on proteins

produced in insect cells. The primary structures of these glycans are not different from those found on certain mammalian proteins such as ribonuclease B, thyroglobin, tissue plasminogen activator (the latter one has a mixed population of high mannose and complex structures at its glycosylation sites).

Small mammalian cells cultures are practical for use in laboratory mammalian gene expression experiments. However, the cost and difficulties of expressing large quantities of therapeutic recombinant glycoproteins in mammalian cell cultures are prohibitive. Therefore, there is a need for a host that is capable of producing large quantities of recombinant proteins that possess, or can be modified to possess, a glycosylation pattern that is similar to that produced by mammalian cells.

Filamentous fungi, for example, *Trichoderma*, have certain advantages as recombinant hosts. It is easy to grow large amounts of these fungi and they have the ability to glycosylate and efficiently secrete large yields of recombinant mammalian proteins into the medium, making isolation relatively easy. In addition, the glycosylation pattern on such proteins is more similar to humans than that of baker's yeast. However, there are still differences, which places wild-type fungal glycosylation patterns at a structural and functional disadvantage when *in vivo* efficacy of a protein requires a specific type of glycosylation. For example, terminal sialic acid residues are important to the functioning of a protein in a mammalian system, as they impede glycoprotein clearance from the mammalian bloodstream. The mechanism behind the increased biologic half-life of sialylated molecules is believed to lie in their decreased recognition by lectins (Drickamer, K., *J. Biol. Chem.* 263:9557-9560 (1988)). However, fungal cells are not capable of adding such units. Glycoproteins synthesized in fungal cells are asialic.

Another disadvantage presented by the inability to generate complex glycoprotein moieties lies in the presence of terminal mannose residues. Glycoproteins terminating in mannose residues are ligands for mannose-binding proteins on macrophages and cells from the reticulo-endothelial system (Ezekowitz *et al.*, *J. Cell Sci. Suppl.* 9:121-133 (1988)). While this can be useful

in some limited instances, as for targeting purposes, this has an undesirable pharmacological consequence for most recombinant proteins — e.g., the rapid clearance of the compound from the blood. Rapid clearance may deleteriously effect the administered agent's pharmacokinetics and decrease its therapeutic potential or increase its toxicity. Thus, recombinantly produced non-complex glycosylation patterns hamper the use of recombinantly made glycoproteins for human therapeutic use (Sareneva, T. *et al.*, *Interferon Res.* 13:267-269 (1993)).

These disadvantages may block the biological or pharmacologic usefulness of mammalian proteins generated using fungal transformation systems. Therefore, there has been a long-felt need in the glycoprotein industry to devise an (*in vitro*) glycosylation system that would provide complex type glycosylation patterns similar to those found on proteins from the higher eukaryotes.

### *Summary of the Invention*

Recognizing the need for the large scale, economical production of recombinant proteins that have a mammalian glycosylation pattern, the inventors have investigated glycosyl residue processing in mammalian and fungal cells. These studies have led to the discovery that filamentous fungi such as *Trichoderma* are capable of secreting a desired protein in an immature glycosylated precursor form that is amenable to *in vitro* processing to a hybrid type mammalian glycosylation pattern. This discovery has resulted in the development of methods of preparing hybrid and complex protein glycosylation patterns, similar to those found in mammalian hosts.

Accordingly, in a first embodiment, the glycosylation pattern of a desired glycosylated protein (glycoprotein) is sequentially modified by reaction with N-acetylglucosaminyl-transferase I (GlcNAc Tr I), galactosyltransferase and sialyltransferase, so as to produce a protein having a hybrid-type glycosylation pattern with terminal sialic acid(s) similar to that of mammalian cells.

Accordingly, in a further embodiment, the glycosylation pattern of a desired glycosylated protein is sequentially modified first by reacting such protein with  $\alpha$ -1,2-mannosidase, to improve reaction with GlcNAc Tr I, galactosyltransferase and sialyltransferase, so as to produce a hybrid type glycosylation pattern with a terminal sialic acid residue(s) similar to that of mammalian cells.

Accordingly, in a further embodiment, glycosylated proteins are expressed in, and preferably secreted from, a fungal host that has been transformed with GlcNAc Tr I, and modified by sequential reaction with galactosyltransferase and sialyltransferase so as to produce a hybrid-type glycosylation pattern with terminal sialic acid, a structure similar to that of mammalian cells.

Accordingly, in a further embodiment, the glycosylation pattern of the desired glycosylated protein produced in a fungal host, preferably *Trichoderma*, that has been transformed with  $\alpha$ -1,2-mannosidase and/or GlcNAc Tr I, is modified by reacting such protein sequentially with GlcNAc Tr I, if necessary, and with galactosyltransferase and sialyltransferase, so as to produce a protein having a hybrid-type glycosylation pattern with a terminal sialic acid structure similar to that of mammalian cells.

Accordingly, in a further embodiment, the immature glycosylated form of a desired glycosylated protein is produced in a fungal host, preferably *Trichoderma*, that has been transformed with a recombinant gene encoding  $\alpha$ -1,2-mannosidase and/or GlcNAc Tr I, preferably human GlcNAc Tr I, and is further modified by *in vitro* reaction with non-specific mannosidase, so as to produce a protein having a mono-antennary complex glycosylation pattern in one *in vitro* step.

Accordingly, in a further embodiment, any of the above proteins having a hybrid type glycosylation pattern are converted to a complex pattern by reactions with an  $\alpha$  1,2-;  $\alpha$  1,3-; and/or  $\alpha$  1,6- mannosidase.

### *Brief Description of the Figures*

Figure 1. Figure 1 is a diagram that illustrates the conversion of high mannose oligosaccharides (glycosyl structures) to hybrid oligosaccharides after the reaction of high mannose structures with  $\alpha$ -1,2 mannosidase, GlcNAc Tr I,  $\beta$ -1,4 galactosyl transferase (shown as GalTr), and  $\alpha$ -2,6 sialyltransferase (shown as NeuNAc T). The conversion of fungal glycoprotein high mannose oligosaccharides (glycosyl structures) to hybrid structures occurs as a result of this illustrated series of reactions.

Figure 1A. Figure 1A is a diagram that illustrates the conversion of hybrid oligosaccharides (glycosyl structures) to complex type oligosaccharides after the reaction of hybrid structures with an aspecific (non-specific)  $\alpha$ -mannosidase.

Figure 2. Figure 2 shows a map of plasmid pCAGGS. The major divisions are lengths of 1000 bp, the subdivisions are lengths of 200 bases. The length is approximately 4811 bp. AG: $\beta$ -actin/ $\beta$ -globin hybrid promoter; SVORI:bidirectional origin of SV40; RBS: *lac* operon ribosome binding site; polyA: polyA signal of the SV40 early region (clockwise arrow) or late region (counterclockwise arrow); Ori: Eco-pMBI origin or plasmid replication; AMP: ampicillin resistance gene; CMV: CMV-IE enhancer; lac: lac promoter; rGBf (plasmid bases 10-182): partial exon 3 and 3' untranslated region and poly A site of the rabbit  $\beta$ -globin gene; 3FR (plasmid bases 183-541): 3'-flanking region of rabbit  $\beta$ -globin gene.

Figure 3. Figure 3 shows a map of plasmid pSCGAL1MF3. The major divisions are lengths of 500 bp, the subdivisions are lengths of 100 bases. The length is approximately 3477 bp. AMP: ampicillin resistance gene; ORI: origin of plasmid replication (Eco-pMB1); lac: lac promoter; RBS: *lac* operon ribosome binding site; GAL1: Gal1 promoter, PREMF:  $\alpha$ -mating factor 1 prepro sequence; lacZ: LacZ $\alpha$  gene.

Figure 4. Figure 4 shows a map of plasmid pCAMFhGNTIf<sub>1</sub>, containing a human gene fragment encoding N-acetylglucosaminyltransferase I (hGlcNAc-Tr



D). The major divisions are lengths of 1000 bp, the subdivisions are lengths of 200 bases. The length is approximately 6223 bp. AMP: ampicillin resistance gene; ORI: origin of plasmid replication (Eco-pMB1); lac: lac promoter, RBS: *lac* operon ribosome binding site; PREMF:  $\alpha$ -mating factor 1 prepro sequence; rGBf (plasmid bases 1-170): partial exon 3 and 3' untranslated region and poly A site of the rabbit  $\beta$ -globin gene; 3FR (plasmid bases 171-530): 3'-flanking region of rabbit  $\beta$ -globin gene; SVORI: bidirectional origin of replication of SV40; poly A: poly A signal of the SV40 early (clockwise arrow) or late region (counterclockwise arrow); CMV: CMV-IE enhancer; Ac: chicken  $\beta$ -actin promoter.

Figures 4A, 4B, 4C and 4D show the sequential construction of pCAMFhGNTIf1. All abbreviations are as above. Figure 4A diagrams the insertion of the hGNTI fragment into pUC18; figure 4B diagrams the extraction of the GAL1-PREMF fragment from pSCGAL1MF3 and its insertion into pUC18; Figure 4C diagrams the construction of the pUC18 plasmid that contains the hGNTI sequence (without its signal sequence) after the PREMF signal sequence; and Figure 4D diagrams the final construction of pCAMFhGNTIf1 by inserting the PREMF-hGNTI fragment that had been taken from the vector constructed in Figure 4C into pCAGGS.

Figure 5. Figure 5 shows an autoradiogram that was obtained after exposure of an X-ray film to radiolabelled glycoproteins that had been separated on an SDS-polyacrylamide gel electrophoresis (SDS-PAGE). The following GlcNAc Tr I substrates were added as noted: Lane 1, no substrate protein added; lane 2, human transferrin added as a negative control; lane 3, *S. cerevisiae* invertase added as a negative control; lane 4, ovalbumin added as a positive control; lane 5, cellulases from *Trichoderma*; lane 6, proteins secreted from *T. reesei* mutant RUTC 30.

Figure 6. Figure 6 shows an autoradiogram that was obtained after exposure of an X-ray film to radiolabelled oligosaccharide structures that had been separated on a thin layer chromatography plate (TLC). The following were added

to the reaction mixture containing GlcNAc Tr I: Lane 1, no oligosaccharides added to reaction; lanes 2 and 3, high mannose oligosaccharides from ribonuclease B hydrazinolysis, Oxford Glycosystems, (lane 2), and, Man<sub>5</sub>Gn from mannosidosis urine, Sanbio, (lane 3), were reacted as positive controls; lane 4, oligosaccharides isolated from *Trichoderma* cellulases; lane 5, oligosaccharides isolated from secreted proteins from *T. reesei* mutant RUTC 30; lane 6, glycosyl structures released from *S. cerevisiae* invertase as negative control.

Figure 7. Figure 7 shows an autoradiogram that was obtained after exposure of an X-ray film to radiolabelled glycoproteins that had been separated on 12.5% SDS-PAGE. Lane 1, the incorporation of radioactive 2-deoxy-2-N-acetylamin-D-glucose (GlcNAc) on CBH I is shown; lane 2, a clear electrophoretic shift of CBH I was the consequence of the incorporation of radioactive sialic acid is shown.

Figure 8. Figure 8 shows the electrophoretic resolution of ANTS-oligosaccharides prepared from *T. reesei* RUTC 30 glycoproteins. Lane 1: the CBH I digest; lane 2: CBH I oligosaccharides treated with *A. saitoi*  $\alpha$ -1,2-mannosidase; lane 3: digest from a mixture of *T. reesei* RUTC 30 secreted proteins; lane 4: analogous to lane 3, but with  $\alpha$ -1,2-mannosidase treatment; lane 5: bovine ribonuclease B digest; M: molecular weight markers (a: maltotetraose; b: maltopentaose; c: maltohexaose; d: maltoheptaose; e: maltooctaose; f: maltononaose).

Figure 9. Figure 9 shows an autoradiogram of a thin layer chromatogram as above, separating free oligosaccharides pretreated with  $\alpha$ -1,2 mannosidase and subsequently treated with GlcNAc Tr I and UDP-(<sup>14</sup>C)GlcNAc (uridine diphospho-2-deoxy-2-N-acetylamin-D-<sup>14</sup>C-glucose). To the GlcNAc Tr I reaction mixtures, the following were added: Lane 1, oligosaccharides were not added; lane 2, Man<sub>5</sub>GlcNAc (Sanbio), an acceptor substrate for GlcNAc Tr I, was added as a positive control; lanes 3 and 4, respectively, *S. cerevisiae* invertase oligosaccharides not pretreated and pretreated with  $\alpha$ -1,2 mannosidase; lanes 5 and 6, respectively, oligosaccharides from *Trichoderma* cellulases (Fluka, Buchs,

Switzerland) not pretreated and pretreated with  $\alpha$ -1,2 mannosidase; lanes 7 and 8, respectively, oligosaccharides from *T. reesei* mutant RUTC 30 not pretreated and pretreated with  $\alpha$ -1,2 mannosidase.

Figure 10. Figure 10 shows an autoradiogram of an SDS-PAGE separating glycoproteins reacted with GlcNAc Tr I and UDP-( $^{14}$ C)GlcNAc, with or without "pretreatment" with *A. Saitoi*  $\alpha$ -1,2 mannosidase. Lanes 1 and 2, respectively, no protein acceptor substrate without and with  $\alpha$ -1,2 mannosidase treatment; lanes 3 and 4, respectively, transferrin without and with pretreatment with  $\alpha$ -1,2 mannosidase; lanes 5 and 6, respectively, *S. cerevisiae* invertase without and with pretreatment with  $\alpha$ -1,2 mannosidase; lanes 7 and 8, respectively, ovalbumin without and with pretreatment with  $\alpha$ -1,2 mannosidase; lanes 9 and 10, respectively, *Trichoderma* cellulases (Fluka, Buchs, Switzerland) without and with pretreatment with  $\alpha$ -1,2 mannosidase.

Figure 11. Figure 11 shows an autoradiogram of a 12.5% SDS-PAGE gel containing various proteins reacted with GlcNAc Tr I and UDP-( $^{14}$ C) GlcNAc. Lane 1 is  $\alpha$ -amylase from *Aspergillus oryzae*. Lane 2 is  $\alpha$ -amylase from *Aspergillus niger*. Lane 3 is an ovalbumin (positive control). Lane 4 is no protein (negative control). Lane 6 is papain digested cellobiohydrolase I from *Trichoderma reesei* RUTC 30. Lane 7 is a galactosidase isolated from *Aspergillus oryzae*. The markers (M) are "rainbow" [ $^{14}$ C] labeled marker proteins from Amersham, Buckinghamshire, UK.

Figure 12. Figure 12 shows an autoradiogram of a thin layer chromatograph demonstrating formation of hybrid structures at the oligosaccharide level. Lane 1 shows \*GlcNAc transferred to Man<sub>3</sub> GlcNAc<sub>2</sub> from ribonuclease B. Lane 2 shows \*Gal linked to \*GlcNAc on commercial Man<sub>3</sub> GlcNAc<sub>2</sub>. Lane 3 shows \*sialic acid transferred to \*Gal linked to \*GlcNAc on commercial Man<sub>3</sub> GlcNAc<sub>2</sub>. Lanes 4, 5, and 6 are analogous to lanes 1, 2, and 3, respectively, but the acceptor substrates are N-glycans liberated from proteins secreted by *Trichoderma reesei* RUTC 30.

### ***Detailed Description of the Preferred Embodiment***

In the following description, reference will be made to various methodologies known to those skilled in the art of molecular genetics, microbiology and general biology. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full.

General principles of glycoprotein biology and of glycoprotein structural analysis are set forth, for example, in *Glycoprotein Analysis in Biomedicine*, edited by E. F. Hounsell, Humana Press, Totowa, New Jersey (1993), and in *Cell Surface and Extracellular Glycoproteins, Structure and Function*, edited by D.D. Roberts and R.P. Mecham, Academic Press, Inc., San Diego, CA (1993).

General principles of the biochemistry and molecular biology of the filamentous fungi and *Trichoderma* are set forth, for example, in Finkelstein, D.B. *et al.*, eds., *Biotechnology of Filamentous Fungi: Technology and Products*, Butterworth-Heinemann, publishers, Stoneham, MA (1992), and Bennett, J.W. *et al.*, *More Gene Manipulations in Fungi*, Academic Press - Harcourt Brace Jovanovich, publishers, San Diego, CA (1991).

#### ***I. Definitions***

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. In the description that follows, a number of terms used in glycoprotein technology are extensively utilized. In order to provide a clear and consistent understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

"Glycosylation pattern" refers to a characteristic structure, number or location of oligosaccharide structures associated with a macromolecule, such as a protein, or typical of a specific cell type or species.


"Wild-type glycosylation pattern" refers to the characteristic native structure, number or location of oligosaccharide structures that are associated with a macromolecule, such as a protein, or found on a specific cell type or species.


"O-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through threonine or serine.

"N-linked" oligosaccharides are those oligosaccharides that are linked to a peptide backbone through asparagine, by way of an asparagine-N-acetylglucosamine linkage. The N-linked oligosaccharides are also called "N-glycans." All N-linked oligosaccharides have a common pentasaccharide core of  $\text{Man}_3\text{GlcNAc}_2$  (Mannose<sub>3</sub>GlucoseNAcetyl<sub>2</sub>) (Glucose can be abbreviated as Glc and Gluc). They differ in the presence of, and in the number of branches (also called antennae) of peripheral sugars such as fucose and sialic acid.

N-linked oligosaccharides are categorized according to their branched constituents. If the branched constituent is only mannose, the oligosaccharide is said to be a "high mannose N-glycan." As used herein "high mannose" or "high-mannose type" oligosaccharide or glycosyl structure means an oligosaccharide with additional  $\alpha$ -mannose residues linked to the outer core structure  $\text{Man}_3\text{GlcNAc}_2$ , and no fucose or sialic acid residues at the free ends of the oligosaccharide branches.

A "complex" or "complex-type" oligosaccharide or glycosyl structure means the structure of an oligosaccharide with typically two to six outer branches with a sialyllactosamine sequence linked to an outer core structure  $\text{Man}_3\text{GlcNAc}_2$ . A complex N-glycan has at least one branch, and preferably at least two, of alternating GlcNAc and galactose (Gal) residues that terminate in oligosaccharides such as, for example: NeuNAc-; NeuAc $\alpha$ 2-6GalNAc $\alpha$ 1-; NeuAc $\alpha$ 2-3Gal $\beta$ 1-3GalNAc $\alpha$ 1-; NeuAc $\alpha$ 2-3/6Gal $\beta$ 1-4GlcNAc $\beta$ 1-; GlcNAc $\alpha$ 1-4Gal $\beta$ 1- (mucins only); Fuc $\alpha$ 1-2Gal $\beta$ 1- (blood group H);





Sulfate esters can occur on galactose, GalNAc, and GlcNAc residues, and phosphate esters can occur on mannose residues. NeuAc (Neu: neuraminic acid; Ac:acetyl) can be O-acetylated or replaced by NeuGI (N-glycolylneuraminic acid). Complex N-glycans may also have intrachain substitutions of bisecting GlcNAc and core fucose (Fuc).

"Hybrid N-glycans" have only mannose residues on the  $\text{Man}\alpha 1-6$  arm of the core and one or two complex antennae on the  $\text{Man}\alpha 1-3$  arm.

An "acceptor substrate" is an oligosaccharide, the specific structure of which is recognized as a substrate by an enzyme, such that reaction with such enzyme adds certain sugar residues to said acceptor substrate. For example, the oligosaccharide  $\text{Man}_3\text{GlcNAc}_2$  is an acceptor substrate for GlcNAc Tr I, the first glycosyltransferase involved in complex carbohydrate formation.

By an "immature precursor" glycosylation pattern, or N-glycan structure is meant a high mannose structure. According to the invention, "immature" structures can be "matured" to a hybrid or complex type structure by treatment with enzymes that add the appropriate units of the hybrid or complex-type oligosaccharides, with or without the removal of the mannose residues as necessary.


By "sequentially modified" is meant that an oligosaccharide (glycan) structure is enzymatically modified in an ordered manner, involving two or more enzymatic reaction such that at least one reaction precedes the other. This is also referred to as a "cascade" series of enzymatic reactions.

By "reacting a protein with an enzyme" is meant that the protein is provided in a reaction mixture that contains all the required components for catalyzing the enzyme's inherent activity to modify such protein.


Linkage between monosaccharides units in a glycan can be to any of the hydroxyl groups with either a  $\beta$  or an  $\alpha$  anomeric configuration. When drawn as shown below (for example at carbon 1 ("1" below) of GlcNAc and sialic acid), the  $\beta$  or  $\alpha$  configuration is depicted as a line above or below the plane of the monosaccharide ring, respectively.



The pyranose form of  $\beta$ -D-N-acetylglucosamine (GlcNAc) is:



The structure of sialic acid is:



where  $R = \text{CH}_3\text{-CO-(N-acetylneuraminic acid)}$ , or  $\text{CH OH-CO-(N-glycolylneuraminic acid)}$ ; the hydroxyl groups can be substituted with different acyl substituents and those at C8 and C9 with additional sialic acid residues.


Certain abbreviations are used herein as are common in the art, such as: "Ac" for acetyl; "glc" for glucose; "fuc" for fucose; "GlcNAc" for N-acetylglucosamine; "man" for mannose; "PNGase F" for peptide N-glycosidase F (EC 3.2.2.18).

As used herein, "GlcNAc Tr I" means N-acetylglucosaminyl-transferase I.


## II. The Glycosylation Pathway

In glycoproteins, potential N-glycosylation sites contain the sequence asparagine-X-serine (or threonine), where X can be any amino acid except proline. Proteins can be engineered to contain artificial N-glycosylation sites, or the natural site may be used.


The methods of the invention will be better understood by reference to the glycosylation pathway as described below. It is believed that the early events of N-glycan synthesis that are executed in the endoplasmic reticulum are identical in yeasts, plants and higher eukaryotes and fungi. The pathway of N-glycosylation of proteins in eukaryotic cells generally follows this pattern. First, a lipid-linked precursor oligosaccharide (I):



is transferred from the lipid and attached an Asn on the target protein through the action of an oligosaccharyltransferase to form (II):




This is also abbreviated:  $\text{Glc}_3\text{Man}_9\text{GlcNAc}_2\text{-protein}$ . The enzyme  $\alpha$ -1,2 glucosidase I then removes the terminal glucose residue, and  $\alpha$ -1,3 glucosidase II removes the second and third glucose residues to leave (III):




This is an example of a "high-mannose type" glycosylation. This is also abbreviated:  $\text{Man}_9\text{GlcNAc}_2\text{-protein}$ .

The final step in the rough endoplasmic reticulum is the removal of one mannose residue. Remaining steps are performed in endoplasmic reticulum (ER) and the Golgi apparatus. Up to this point, the glycosylation pathway of both yeast and mammalian cells is the same. However, steps in the cis-Golgi differ between yeast and the higher eukaryotes. Yeast add mannoses by the action of


mannosyltransferases, the result of which is a high mannose type glycosylation in the glycosylated product. However, higher eukaryotes remove three additional mannoses, with  $\alpha$ -mannosidase I; in some cases, this trimming also takes place in the ER. The result is the product (IV):




This is also a "high mannose" structure and is abbreviated:  $\text{Man}_5\text{GlcNAc}_2\text{-protein}$ . The high energy sugar nucleotide, UDP-GlcNAc, serves as a substrate for GlcNAc Tr I to transfer a GlcNAc moiety to (IV) to produce (V):



This is a hybrid-type structure and is abbreviated: GlcNacMan<sub>3</sub>GlcNac<sub>2</sub>-protein.  $\alpha$ -Mannosidase II recognizes this substrate and removes additional mannose residues to result in the "hybrid type" structure (VI):



This is abbreviated: GlcNacMan<sub>3</sub>GlcNac<sub>2</sub>-protein. This can serve as a substrate for any of UDP-GlcNAc, UDP-Gal or CMP-sialic acid (SA), and GlcNAc-transferase II, galactosyltransferase or sialyltransferase, respectfully, to yield a "complex type" glycosylation pattern, for example, as shown below (VII):



### III. Glycosylation Modification Enzymes

The glycosylation modification enzymes that are useful in the methods of the invention include transferases and mannosidases. Mannose residues that are linked by an  $\alpha 1,2$  linkage are those mannose residues that can be removed *in vivo*

or *in vitro* by a "specific"  $\alpha$ 1,2 mannosidase, such as that of *Aspergillus saitoi*. GlcNAc Tr I is very specific and only transfers GlcNAc to the less periferic  $\alpha$ 1,3-linked mannose of a  $\text{Man}_3\text{GlcNAc}_2$  structure (an appropriate substrate is shown as structure IV, above). After transfer of GlcNAc, galactose and sialic acid to  $\text{Man}_3\text{GlcNAc}_2$ , the remaining  $\alpha$ 1,3 and  $\alpha$ 1,6-linked mannose residues can be removed *in vivo* or *in vitro* using an "aspecific" mannosidase such as, for example, the commercially available Jack bean mannosidase, thus converting a hybrid structure to a complex one.

Transferases such as the GlcNAcTr I, galactosyltransferase and sialyltransferase exemplified herein, catalyze the transfer of a monosaccharide from a high-energy sugar donor to an acceptor oligosaccharide. The generalized reaction is: sugar nucleotide + acceptor  $\Rightarrow$  acceptor sugar + nucleotide.

To follow the reaction *in vitro*, a sugar nucleotide can be provided in a form that will label the acceptor. For example, the specific activity of the commercial radiolabelled sugar nucleotides is sufficiently high to allow detection of fmoles of acceptor substrate in a radiolabelled assay.

Neither glycosyltransferases nor the sugar nucleotide substrates are permeable to cell membranes. This allows the extracellular alteration of cell surface glycosylation on intact cells or sealed membrane preparations, using the method of the invention in those embodiments wherein the GlcNAc Tr I reaction does not occur within the host cell.

GlcNAcTr I (EC 2.4.1.101) is the medial Golgi transferase that initiates complex N-linked carbohydrate formation. This enzyme is also known as UDP-N-acetylglucosamine: $\alpha$ -3-D-mannoside  $\beta$  1,2-N-acetylglucosaminyltransferase I. The human gene encoding this enzyme has been cloned and its coding sequence published (Kumar, R. *et al.*, *Proc. Natl. Acad. Sci., USA* 87:9948-9952 (1990). Other GlcNAc Tr I sources include rabbit (Sarkar, M. *et al.*, *Proc. Natl. Acad. Sci. USA* 88:234-238 (1991) and mouse (Kumar, R. *et al.*, *Glycobiology* 2:383-393 (1992)).

Other enzymes useful in the construction of the hybrid oligosaccharide, as shown in Figure 1, are also available and have been cloned. For example, a non-limiting list includes bovine  $\beta(1,4)$ galactosyl transferase (D'Agostaro, G. *et al.*, *Eur. J. Biochem.* 183:211-217 (1989), human  $\beta(1,4)$ galactosyl transferase (Masri, K.A. *et al.*, *Biochem. Biophys. Res. Commun.* 157:657 (1988), rat  $\alpha(2,6)$ sialyltransferase (Wang, X.C. *et al.*, *Glycobiology* 1:25-31 (1990), and rabbit  $\alpha 1,2$  mannosidases (Lal, A. *et al.*, *J. Biol. Chem.* 269:9872-9881 (1994)) or with mouse  $\alpha 1-2$  mannosidases (Herscovics, A. *et al.*, *J. Biol. Chem.* 269:9864-9871 (1994).

To clone a reported sequence, primers may be designed based upon the reported sequence. For example, primers such as those of SEQ ID No: 1 and SEQ ID No: 2 can be used to amplify the coding sequence of human GlcNAc Tr I, for example, using PCR techniques, so as to insert such coding sequence into any vector of choice, and preferably an expression vector capable of expression of such coding sequence in a desired host.

The GlcNAc Tr I enzyme is not glycosylated. Mouse GlcNAc Tr I has been expressed by Kumar, R. *et al.*, *Glycobiology* 2:383-393 (1992). It is possible and useful to express mouse and human GlcNAc Tr I intracellularly in bacteria, but it may form protein aggregates. For this reason, intracellular production in bacteria is not the preferred method for the production of GlcNAc Tr I. The enzyme can be produced in mammalian cells such as COS cells, be secreted into the medium, and used directly in that medium if desired; it should be noted that use of the enzyme in the spent growth medium is simply for convenience; the cell's growth medium environment is not necessary *per se* for GlcNAc Tr I activity as the enzyme produced in bacteria was active. Isolation methods for the enzyme from rabbit liver are also known (Nishikawa, Y. *et al.*, *J. Biol. Chem.* 263:8270-8281 (1988)).

In the methods of the invention, GlcNAcTr I reactions are preferably run at 37°C. One unit is that enzyme activity that catalyzes transfer of 1  $\mu$ mol GlcNAc from UDP-GlcNAc to Man<sub>5</sub>GlcNAc within 1 minute at 37°C and pH 6.1.

As exemplified, 330  $\mu$ mol acceptor substrate and 340  $\mu$ mol UDP-GlcNAc were used with 10-15  $\mu$ l of a 10-fold concentrated COS supernatant (containing about 30 microunits GlcNAc Tr I in a reaction mixture with a final volume of 30  $\mu$ l. One unit of enzyme activity converts 1  $\mu$ mol substrate in one minute. Reaction times will vary depending upon the concentration and specific activity of the enzyme, but generally 5-10 hours, and, as exemplified, 1-4 hours, are sufficient for the purposes of the methods of the invention. The GlcNAc Tr I reaction can be run for a longer time as the scale of the reaction is increased (Ichikawa *et al.*, *Anal. Biochem.* 202:215-238 (1992)).

The enzymes do not need to be pure to be useful, as exemplified using the COS cell medium as a source of GlcNAc Tr I. However, large scale isolation of the glycosyltransferases can be achieved using nucleotide-affinity adsorbents as known in the art. The glycosyltransferase may be modified by the addition of an affinity tag (such as the streptavidine-tag or a histidine-tail) in order to enhance purification and reduce purification costs.

$\beta$ -1,4 Galactosyl transferase, EC 2.4.1.38, such as that from human milk exemplified herein, is commercially available from Boehringer Mannheim (catalog no. 1088-696), and Sigma Chemical Co., St. Louis, Missouri. Its purification from bovine milk was reported by Barker, R. *et al.*, *J. Biol. Chem.* 247:7135 (1972). In the presence of  $\alpha$ -lactalbumin, EC 2.4.1.38 becomes EC 2.4.1.22, lactose synthetase (also known as lactose synthase and UDP-D-galactose: D-glucose 4 $\beta$ -galactosyltransferase), and accepts glucose as a substrate for the transfer of galactose to produce lactose (Yoon *et al.*, *Glycobiology* 2:161-168 (1992)). This enzyme is commercially available from Sigma and Oxford Glycosystems. It is also easy to purify (Barker, R. *et al.*, *J. Biol. Chem.* 247:7135 (1972)). Bovine galactosyl transferase can be used in the same way and under the same reaction conditions as that from human. Cloned  $\beta$ -1,4 galactosyl transferase has been expressed in several systems (see, Masibay, A. *et al.*, *Proc. Natl. Acad. Sci. USA* 86:5733-5737 (1989), Aoki, D. *et al.*, *EMBO J.* 9:3171 (1990) and Krezdorn, C. *et al.*, *Eur. J. Biochem.* 212:113-120 (1993)).



The enzymatic reaction conditions of  $\beta$ -1,4 Galactosyl transferase, EC 2.4.1.38, are known in the art (Parchment, R.E. *et al.*, *Anal. Biochem.* 154:460-469 (1986); Nunez, H. and Barker, R., *Biochemistry* 19:489-495 (1980)). The enzyme requires a pH of 8-8.5 and 1-50 mM manganese, preferably 20 mM, for optimal enzymatic activity. Reactions are preferably run at 37°C, with about 65 mU enzyme and 5  $\mu$ mol UDP-galactose per ml. One unit of enzyme activity is the enzyme activity that catalyzes transfer of 1  $\mu$ mol galactose from UDP-galactose to glucose in the presence of  $\alpha$ -lactalbumin, in 1 minute at 37°C and pH 8.4. However, for commercially available galactosyl transferase (5.5 units per mg), in the absence of  $\alpha$ -lactalbumin and with GlcNAc as the substrate, the enzymatic activity may be reduced, for example, to about 3.5 U/mg. Reaction times will vary depending upon the concentration and specific activity of the enzyme, but generally 6-10 hours for small scale, and, as exemplified, 8 hours, are sufficient for the purposes of the methods of the invention. Longer times may be necessary as the scale of the reaction is increased.

$\alpha$ -2,6 Sialyltransferase, EC 2.4.99.1, such as that from rat liver exemplified herein, is commercially available from Boehringer Mannheim (catalog no. 981-583), and from Genzyme, Calbiochem, and Sigma. Its purification was reported by Weinstein, J. *et al.*, *J. Biol. Chem.* 257:13,835-13,844 (1982). The enzyme is also known as CMP-N-acetylneuraminic:  $\beta$ -D-galactosyl-1,4-N-acetyl- $\beta$ -D-glucosamine  $\alpha$ -2,6-N-acetylneuraminyltransferase. The  $K_m$  for the sugar donor CMP-NeuAc is  $8.5 \times 10^{-5}$ M. The acceptor sequence is Gal $\beta$ 1,4GlcNAc-R. Purification methods for sialyltransferases involved in N-glycosyl synthesis are known (Weinstein, J. *et al.*, *J. Biol. Chem.* 262:17735-17743 (1987)). Recombinant production of sialyltransferases has been reported in mammalian COS and CHO cells (Schachter, H. *et al.*, in "Molecular Glycobiology," Fukuda, M. *et al.*, eds., IRL Press, pp. 88-162 (1994). The cloning of human  $\alpha$ -2,6 sialyltransferase was reported in Grundmann, U. *et al.*, *Nucleic Acids Res.* 18:667 (1990).

One unit of  $\alpha$ -2,6 sialyltransferase will transfer 1  $\mu$ mol N-acetylneuraminic acid from CMP-N-acetylneuraminic acid to asialo- $\alpha$ <sub>1</sub>-glycoprotein in 1 minute at 37°C (Weinstein, J. *et al.*, *J. Biol. Chem.* 257:13835-13844 (1982)). The enzyme requires a pH of 6-6.5 for optimal activity, and 50 mM NaCl is generally added to the assay to stabilize the enzyme's activity. Reactions are preferably run at 37°C, with about 4-40 mU enzyme, 0.5-5  $\mu$ mol CMP-NANA per ml (100-800  $\mu$ g acceptor protein per ml were used in the exemplified embodiments), and preferably 3.6  $\mu$ mol. Reaction times will vary depending upon the concentration and specific activity of the enzyme, but generally 6-10 hours for small scale syntheses, and longer for large scale application, are sufficient for the purposes of the methods of the invention.

$\alpha$ -1,2 Mannosidase (EC 3.2.1.24), such as that from *Aspergillus saitoi* exemplified herein, is commercially available from Oxford Glycosystems, Oxford, UK. One unit of enzyme is the amount of enzyme that will release one  $\mu$ mole of mannose from bakers yeast mannan per minute at pH 5.0 and 37°C. In the exemplified embodiments, 6  $\mu$ units enzyme were used to treat up to 500  $\mu$ g protein in a 30  $\mu$ l final volume, and 2  $\mu$ units enzyme were used to treat about 5  $\mu$ g bovine ribonuclease B oligosaccharides (Oxford GlycoSystems Cat No. RP-2500) in 10  $\mu$ l final volume. Preferably the pH is about 5.0 for optimal activity of the enzyme from *A. saitoi*. Reactions are preferably run at 37°C.

Methods for detection of the products of these reactions are well known and exemplified herein.

#### **IV. Modification of Glycosylation Patterns**

According to the invention, the modification of glycoproteins may be effected *in vitro* by carbohydrate modifying enzymes described above that are capable of synthesizing or modifying glycosylation structures. Glycoproteins synthesized by yeast, filamentous fungi and insect cells, can be structurally and functionally dissimilar to mammalian-type carbohydrate structures in having a high

mannose or hybrid-type character. However, as embodied by this invention, these high mannose oligosaccharide structures can be enzymatically converted into hybrid or complex structure, making the carbohydrate structure on the yeast, fungi, or insect produced protein more similar to, or identical to, the mammalian-produced carbohydrate structure.

It has been surprisingly discovered that filamentous fungi such as, for example, *Trichoderma*, unlike yeast, synthesize glycoproteins in a form that is recognizable as an acceptor substrate for the enzyme N-acetylglucosaminyl transferase I (GlcNAc Tr I), especially human GlcNAc Tr I. This form is an "immature" mammalian form.

However, GlcNAc Tr I is not naturally present in these hosts. According to the invention, the above finding is exploited such that the glycosylation pattern of a desired glycoprotein, for example, a recombinant protein that was produced in *Trichoderma*, having a structure that can serve as an acceptor substrate for GlcNAc Tr I, for example, formula (IV) above, is modified by a cascade of sequential reactions, for example three sequential reactions with the following enzymes: first, GlcNAc Tr I; second,  $\beta$ -1,4 galactosyl transferase; and third,  $\alpha$ -2,6 sialyltransferase. The result of this cascade is the production of a glycoprotein having at least a hybrid glycosylation pattern, and, when all branch termini are modified, a complex-type glycosylation pattern. Such branches are preferably terminated with terminal sialic acid units, similar to that of mammalian cells, although, as desired other terminal units can be used, such as those described earlier.

As described below, a recombinant host can be prepared such that the first reaction, that of GlcNAc Tr I, is performed *in vivo*, in the host, prior to secretion of the protein.

It has also been surprisingly found that treatment of glycoproteins that have been synthesized by yeast and *Trichoderma*, with  $\alpha$ -1,2-mannosidase, so as to trim (remove) mannose residues from such glycoprotein, provides (in the case of yeast) or enhances (in the case of *Trichoderma*), acceptor substrate sites for

GlcNAc Tr I enzymatic action. According to the methods of the invention, a mannosidase may be used to pretreat the acceptor substrate prior to reaction with GlcNAc Tr I, to create, or otherwise enhance the availability of, target sites of GlcNAc Tr I action on such substrate.

Therefore, in a first embodiment, GlcNAc Tr I activity is used to convert an acceptor substrate of a high mannose type to a hybrid-type. The hybrid type can then be converted to a different hybrid type, or, a complex type. In a highly preferred embodiment, the source of the acceptor substrate for GlcNAc Tr I is a glycoprotein that has been produced in a filamentous fungi, and especially *Trichoderma*, and most especially *T. reesei*.

It is not necessary to extract the product of each reaction from the mixture prior to starting the subsequent reaction. The pH and assay conditions (such as the addition of divalent cations) can simply be adjusted in the same container for each subsequent reaction so that handling is minimized. Additionally, solid state technology can be used to provide the enzymes on a solid support and the acceptor substrate simply passed through such support or the solid support can be used in batch form.

The glycoprotein source of the acceptor substrate can be the native or recombinant glycoprotein product of any host that provides such glycoprotein in useable form. Especially, the glycoprotein is a native or recombinant product of a filamentous fungi, for example, a member of the genera *Absidia*, *Acremonium*, *Alternaria*, *Aspergillus*, *Aureobasidium*, *Beauveria*, *Ceratocystis*, *Chaetomium*, *Cladosporium*, *Collectotrichum*, *Fusarium*, *Gliocladium*, *Mortierella*, *Mucor*, *Paecilomyces*, *Penicillium*, *Phanerochaete*, *Phytophthora*, *Pythium*, *Rhizopus*, *Trichoderma*, and *Verticillium*. Most especially, the host is a member of the *Aspergillus* or *Trichoderma* genera.

*Trichoderma* species useful as hosts for the production of substrate acceptors of GlcNAc Tr I include *T. reesei*, such as QM6a, ALKO2442 or CBS383.78 (Centraalbureau voor Schimmelcultures, Oosterstraat 1, PO Box 273, 3740 AG Baarn, The Netherlands, or, ATCC13631 (American Type Culture

Collection, 12301 Parklawn Drive, Rockville, Maryland, 10852, USA, type); *T. viride* (such as CBS189.79 (det. W. Gams); *T. longibrachiatum*, such as CBS816.68 (type); *T. pseudokoningii* (such as MUCL19358; Mycothèque de l'Université Catholique de Louvain); *T. saturnisporum* CBS330.70 (type); *T. harzianum* CBS316.31 (det. W. Gams); *T. virgatum* (*T. pseudokoningii*) ATCC24961. Most preferably, the host is *T. reesei* and especially *T. reesei* strains QM9414 (ATCC 26921), RUT-C-30 (ATCC 56765), and highly productive mutants like VTT-D-79125, which is derived from QM9414 (Nevalainen, Technical Research Centre of Finland Publications 26, (1985), Espoo, Finland). The transformation of *Trichoderma* may be performed by any technique known in the art, including the technique taught in European patent application EP 244,234.

Preferred species of *Aspergillus* that are useful hosts in the methods of the invention include *A. nidulans*, *A. awamori* and *A. niger*. Methods for the transformation of *Aspergillus* are known.

As described below, when pretreated *in vitro* with  $\alpha$ 1,2 mannosidase, yeast such as *Pichia* spp. (especially *Pichia pastoris*), *Hansenula* spp. (especially *Hansenula polymorpha*), *Kluyveromyces lactis*, *Yarrowia lipolytica*, or *S. cerevisiae* are useful hosts for expressing a gene of interest. Yeast would be useful as a host for expressing cloned GlcNAc TrI enzyme since it is not glycosylated.

In one embodiment, the glycoprotein acceptor substrate is secreted into the growth medium of the production host and is modified *in vitro* by the action of enzymes such as GlcNAc Tr I without being removed from such medium. If desired, the medium can be concentrated prior to enzymatic modification of the gene product of interest. Alternatively, the glycoprotein acceptor substrate can be provided to the GlcNAc Tr I in a purified or isolated form.

In a preferred embodiment of the invention, the coding sequence of GlcNAc Tr I is transformed into a desired host cell from which it is also desired to synthesize the protein of interest, especially, a host cell that does not naturally catalyze the enzymatic modifications according to the methods of the invention.

In this embodiment, the first step in the modification of glycosylation pattern, the reaction catalyzed by GlcNAc Tr I is effected *in vivo*. The host cell then synthesizes, and preferably secretes, an acceptor substrate of a hybrid type. The hybrid type is then converted to a hybrid type that contains terminal sialic acids by the second and third steps of the cascade *in vitro*, that is, the addition of galactose residues with  $\beta$ -1,4 galactosyl transferase, followed by the addition of sialic acid residues with  $\alpha$ -2,6-sialyltransferase.

Preferably, the recombinant host that is transformed with both GlcNAc Tr I coding sequences and, if desired, with the coding sequence for a protein of interest (the glycosylation pattern of which is to be modified *in vivo* by the action of the expressed GlcNAc Tr I). More preferably, the recombinant host is a member of the *Aspergillus* or *Trichoderma* genera as described above.

The recombinant host can also be transformed with DNA comprising the  $\alpha$ -1,2-mannosidase gene. In embodiments of this invention, the recombinant host can be transformed with the  $\alpha$ -1,2-mannosidase gene together with the GlcNAc Tr I coding sequences and, if desired, the coding sequence for a protein of interest. In other embodiments of this invention, the recombinant host is transformed with the  $\alpha$ -1,2-mannosidase gene alone, or, if desired, the coding sequence for the protein of interest.

Vector systems are known that are useful in transforming hosts, especially the *Aspergillus* or *Trichoderma* hosts described above for the production of the GlcNAc Tr I and glycoproteins of the invention. A separate vector may be used to provide the selectable marker.

Expression of genes in a host requires the use of regulatory regions functional in such hosts. A wide variety of transcriptional and translational regulatory sequences can be employed; filamentous fungi such as *Trichoderma* generally recognize eukaryotic host transcriptional controls, such as, for example, those of other filamentous fungi, and especially, *Aspergillus*.

In a preferred embodiment, genetically stable transformants of *Trichoderma* are constructed whereby DNA encoding a desired glycoprotein or

carbohydrate modifying enzyme like GlcNAc Tr I is integrated into the *Trichoderma* host chromosome. The coding sequence for the desired glycoprotein or enzyme may be from any source. Such integration may occur *de novo* within the cell or, in a most preferred embodiment, be assisted by transformation with a vector which functionally inserts itself into the host chromosome, for example, DNA elements which promote integration of DNA sequences in chromosomes.

After the introduction of the vector, recipient cells are grown in a selective medium, which selects for the growth of the transformed cells. Expression of the cloned gene sequence(s) results in the production of the desired glycoprotein and/or carbohydrate modifying enzyme, or in the production of desired fragments thereof. This expression can take place in a continuous manner in the transformed cells, or in a controlled manner, for example, wherein expression is the result of a regulated promoter.

In a preferred embodiment, a desired glycoprotein or carbohydrate modifying enzyme is secreted into the surrounding medium due to the presence of a functional secretion signal sequence, preferably a signal homologous to the host. If a desired gene does not code for a signal sequence, or if its signal sequence does not function well in the host, then the glycoprotein's coding sequence may be operably linked to another signal sequence, either homologous or heterologous to the host, that functions in such host. The desired coding sequence may be linked to any signal sequence which will allow secretion of the glycoprotein from the selected host, for example, for secretion from *Trichoderma*, the signal sequence of the *Trichoderma* cellulase enzymes may be used, for example, the secretion signal of the cellobiohydrolase I (CBHI) cellobiohydrolase II (CBHII), endoglucanase I (EGI) or endoglucanase II (EGII) protein may be used. Secretion signals of the *Trichoderma* xylanases are also useful. Such signal sequences may be designed with or without specific protease sites such that the signal peptide sequence is amenable to subsequent removal.

In those embodiments wherein GlcNAc Tr I is provided intracellularly within the fungal host cell so as to act on a substrate intracellularly, it is not necessary, and not preferable, to secrete recombinantly produced GlcNAc Tr I into the medium as it is necessary that it remain in the host cell to be active *in vivo* in those embodiments.

*Trichoderma* is an especially useful and practical host for the synthesis of the glycoproteins of the invention because *Trichoderma* is capable of secreting protein in large amounts, for example, concentrations as high as 40 g/L culture medium have been reported; the homologous cellulase and hemicellulase promoters such as the *Trichoderma cbh1*, *cbh2*, *egl1* and *egl1* promoters provide very convenient promoters for the high expression of genes of interest because they are strong promoters. For example, the *cbh1* promoter is a single copy promoter that normally directs the synthesis of up to 60% of the secreted protein from the *Trichoderma* host. Alternatively, the gene of interest, or the GlcNAc Tr I gene, can be inserted into the CBHI locus. The *Trichoderma* transformation system is highly versatile and can be adapted for any gene of interest. Culture of *Trichoderma* is supported by previous extensive experience in industrial scale fermentation techniques; for example, see Finkelstein, D.B. *et al.*, eds., *Biotechnology of Filamentous Fungi: Technology and Products*, Butterworth-Heinemann, publishers, Stoneham, MA (1992).

#### V. *Proteins of Interest*

The methods of the invention are useful with any desired protein of interest that contains high mannose-type glycosylation patterns. Such patterns are considered to be "immature" when compared to complex or hybrid patterns.

Especially, a protein of interest may be a protein, such as an immunoglobulin or hormone, that is to be provided to a patient in need of same, especially for therapeutic reasons. Examples of glycohormones wherein glycosylation plays a role in the properties of such hormone, especially the



therapeutic properties, include erythropoietin (EPO), human chorionadotropin (HCG), follitropin (FSH), thyrotropin (TSH) and lutropin (LH). Modification of each peptide subunit according to the methods of the invention may be performed. Examples of other proteins of interest whose biosynthesis, transport or function are altered by N-glycosylation include NCAM, tenascin, thrombospondin, fibronectin, hormones, cytokines, (especially interleukin-4 and interferon gamma), growth factors, plasma proteins, coagulation factors, soluble receptors, immunoglobulins (antibodies), granulocyte-macrophage colony stimulating factor (GM-CSF), vascular endothelial growth factor, HIV virus glycoprotein gp120, viral coat proteins, immunoglobulin D, antithrombin III $\beta$ , plasminogen, von Willebrand factor, fibrinogen, corticosteroid-binding globulin, thyroxine-binding globulin, folate-binding protein, fibrinectin, bone and platelet osteonectin, EGF receptor, insulin and insulin-like growth factor-I receptors, basic fibroblast growth factor receptor, lymphocyte CD2, MHC Class II molecules, glucose transporters, erythrocyte band 3 protein,  $\beta$ -2 adrenergic receptors, transferrin receptor, VIP receptor, membrane class I MHC protein, vasopressin receptor of LLC-PK1 cells, low density lipoprotein receptor, asialoglycoprotein receptor, CD4 protein, thyrotropin receptor, PDGF receptor, jack bean concanavalin A, cobra venom factor, lactotransferrin, spinach chloroplast coupling factor, submaxillary gland mucin, intestinal brush border lactase-phlorizin hydrolase, arctic fish antifreeze glycoprotein, LDL receptor, glucophorin A, and  $\beta$ -HCG, and, generally, secreted animal proteins and plant glycoproteins secreted by sycamore cells in culture. Especially, those proteins that require targeting to specific organs or cells through sugar-lectin recognition are useful protein substrates for modification of glycosylation patterns according to the invention.

The method of the invention is especially useful in designing a protein for use in genetic therapy; in such therapy, a protein, such as an enzyme, that is deficient in a cell or organ, is targeting to such cell or organ by providing such protein with an appropriate glycosylation pattern.

## ***VI. Preparation of Modified Glycoproteins as Pharmaceutical Compositions***

According to this invention, there is provided a method for producing high levels of glycoproteins which are desirable for use, for example, in pharmaceutical compositions. Such glycoproteins may be obtained directly from the hosts of the invention or the culture medium. Further, if desired activities are present in more than one recombinant host (such as multisubunit proteins), such preparations may be isolated from the appropriate hosts and combined prior to use in the method of the invention; alternatively one host can be used to make all subunits of the desired protein.

To obtain the glycoprotein preparations of this invention, the recombinant hosts described above which have the desired properties (that is, hosts capable of expressing the glycoproteins) are cultivated under suitable conditions, the modified glycoproteins are secreted from the *Trichoderma* hosts into the culture medium, and the glycoproteins are recovered from the culture medium by methods known in the art. Alternatively, but less desirably the glycoproteins can be recovered from the host cells themselves.

The glycoprotein is recovered from the culture medium or host cells themselves by using routine methods which are well known in the art. The glycoprotein of the invention may be lyophilized or the glycoprotein otherwise concentrated and/or stabilized for storage. The glycoprotein of the invention are very economical to provide and use. If the glycoproteins are secreted into the culture medium, only the culture medium need be recovered to obtain the desired glycoprotein; there is no need to extract an glycoprotein from the *Trichoderma* hosts unless it is no desire to do so.

If desired, an expressed glycoprotein may be further purified in accordance with conventional conditions, such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis, or the like.

The methods of the invention provide for the manufacture of hybrid or complex glycosyl groups on recombinant glycoproteins for their use as

pharmaceutical agents in a safer and more cost-effective manner than is currently available. The methods of the invention also provide an important benefit in that they result in the synthesis of uniform and well-defined glycosyl structures. Production of a single glycoform can be critical if it is desired to obtain uniform therapeutic pharmacokinetic profiles.

As would be understood by one of ordinary skill in the art, the pharmaceutical compositions of the present invention can be formulated according to known methods to prepare such compositions, whereby the glycoproteins with mammalian-type oligosaccharides are combined with a pharmaceutically acceptable excipient. Suitable excipients and their formulation are described, for example, in *Remington's Pharmaceutical Sciences* (18th ed., Gennaro, A.R., ed.), Mack Publishing Co., Easton PA (1990); see especially Part 4, "Testing and Analysis," pp. 435-602, and Part 8, "Pharmaceutical Preparations and Their Manufacture," pp. 1435-1712). In order to form a pharmaceutically acceptable composition suitable for effective administration, such compositions may additionally contain an effective amount of salts, buffers, adjuvants or other substances which will improve the efficacy of the composition.

Pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved through the use of polymers to complex or absorb the compositions of this invention, their equivalents, or their functional derivatives. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyesters, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of the macromolecules as well as the methods of incorporation in order to control release. Another method to control release is to incorporate the compositions of the invention into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example,

hydroxymethylcellulose or gelatine-microcapsules and poly(methylmethacrylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

The pharmaceutical compositions of the present invention can also be formulated for administration orally, or parenterally by injection (for example by subcutaneous, intramuscular or intravenous injection), by intravenous or other infusion, by nasopharyngeal absorption (intranasopharyngeally), percutaneously, rectally, ocularly or sublingually. Compositions for parenteral administration may include sterile aqueous or non-aqueous solutions, suspensions and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers, adjuncts or occlusive dressings can be used to increase skin permeability and enhance absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include wetting agents, emulsifying and suspending agents, or sweetening, flavoring, coloring or perfuming agents.

In one embodiment, the pharmaceutical compositions of the present invention may be formulated as a cream, lotion, ointment, or the like, for topical administration to the skin. Such compositions may optionally contain wetting agents, emulsifying and suspending agents, or coloring or perfuming agents.

A composition is said to be "pharmacologically acceptable" if its administration can be tolerated by the recipient without the production of serious side effects. Such an agent is said to be administered in a therapeutically "effective" amount or concentration if it produces the desired biologic effect(s).

Generally, the dosage needed to provide an effective amount or concentration of the composition can be adjusted by one of ordinary skill in the art, such as a medical doctor, and will vary depending upon such factors as the route of administration and the recipient's age, condition, sex, and extent of disease, if any, and other variables.

The recipient of the proteins modified according to the methods of the invention can be any animal into which it is desired to administer such protein, including humans, zoo animals, farm animals (bovine, ovine and the like), and pets (cats, dogs, birds, etc.).

The invention is described in more detail in the following examples. These examples show only a few concrete applications of the invention. It is self-evident for one skilled in the art to create additional similar applications and embodiments thereof. Hence the examples should not be interpreted to narrow the scope of the invention but rather only to clarify the use of the invention.

## *Examples*

### *Example 1*

#### *Preparation of Trichoderma reesei Glycoproteins*

Glycoproteins from the *T. reesei* mutant strain RUTC 30 were obtained after growth in a minimal medium for the induction of cellulases (Uusitalo *et al.*, *J. Biotechn.* 17:35-50 (1991)). As carbon sources for growth, lactose or a combination of lactose/cellulose (2% final concentration) were added. The method of Bradford, M. M. (*Anal. Biochem.* 72:248-254 (1976)) was used to measure the concentration of the proteins with immunoglobulin G as a standard. For glycosyltransferase experiments, the secreted proteins were subsequently dialyzed against the proper buffer used in the subsequent glycosyltransferase assay. A fast change to the new buffer was possible without significant loss of the proteins when using Microcon™ ultracentrifugation devices (Amicon) (Blatt

*et al.*, *Anal. Biochem.* 26:151-173 (1968)). A mixture of cellulases from a second, unknown strain of *T. reesei* were commercially obtained from Fluka Chemie, Buchs, Switzerland.

### **Example 2**

#### ***Preparation of Oligosaccharides***

Oligosaccharides were prepared according to a method described by Verostek *et al.* (*Glycobiology* 2:458 (Abstract 1.06) (1992)). Oligosaccharides were released from the glycoproteins (1-20 mg/ml) by recombinant PNGase F (Tarentino *et al.*, *Biochem.* 24:4665-4671 (1985)) (Biolabs). Glycoproteins were first dissolved in 50 mM sodium phosphate (pH 7.5), 0.5% SDS and 1%  $\beta$ -mercaptoethanol, or in 50 mM Tris-HCl, pH 7.0. The proteins were then denatured by boiling for 10 minutes. The nonionic detergent nonidet P-40™ was added to prevent the inhibition of PNGase F by SDS. The reaction mixture was incubated with 1000 units PNGase F at 37°C for 18 hours. After PNGase F treatment, the proteins and oligosaccharides were precipitated by adding four volumes of acetone at minus 20°C. The 80% acetone salt- and SDS-containing supernatant was discarded, and the pellet was extracted twice with ice cold 60% methanol. Methanol was removed from the pooled supernatants after lyophilization by evaporation. Further purification of the oligosaccharides was obtained by passage through a Bio-Gel P2™ column (27 cm high, 0.5 cm diameter, obtained from BIORAD). The presence of oligosaccharides in the different collected fractions was traced through orcinol staining (*Révélateurs pour la chromatographie en couche mince et sur papier*, Merck, p. 91 (1980)). In a second round, pooled oligosaccharide-containing fractions were passed over a Bio Gel P2™ (Biorad) column to obtain oligosaccharides that were sufficiently pure to use in the glycosyltransferase assays.

### Example 3

#### *Amplification of GlcNAc Tr I Genomic DNA Sequence*

The coding region of the GlcNAc Tr I gene (Genbank Accession No. M55621; EMBL Accession No. HSGLCNAC; Kumar *et al.*, *Proc. Natl. Acad. Sci. USA* 87:9948-9952 (1990); all incorporated herein by reference;) from colon carcinoma genomic DNA was amplified using PCR and was subsequently cloned into the mammalian expression-vector pCAGGS which is described in more detail in Table 3 (Figure 2 and described in Niwa *et al.*, *Gene* 108:193-200 (1991)). The human colorectal adenocarcinoma cell line DLD-1 was used as the source of genomic DNA. This cell line is available from the American Type Culture Collection, Rockville, Maryland, (ATCC CCL 221) and is described in *Cancer Research* 39:1020-1025 (1979)). Plasmid pCAGGS was the gift of J. Miyazaki, Univ. Tokyo, Japan. Plasmid pCAGGS is useful for highly efficient expression of genes under the control of the  $\beta$ -actin/ $\beta$ -globin hybrid promoter and CMV-IE enhancer in various mammalian cells. pCAGGS carries a modified chicken  $\beta$ -actin promoter: the splice acceptor sequence of the  $\beta$ -actin promoter region is replaced by a rabbit  $\beta$ -globin fragment containing a 3' part of the second intron and a 5' part of the third exon. The resulting  $\beta$ -actin/ $\beta$ -globin hybrid promoter is designated the "AG" promoter.

Genomic DNA was prepared from colon cells, according to the procedure described by Maniatis, T., "Molecular Cloning, A Laboratory Manual," 2nd edition, Sambrook *et al.*, eds., Cold Spring Harbor Press, Cold Spring Harbor, 1989. A genomic DNA fragment representing the coding region of the GlcNAc Tr I gene was amplified with *Pyrococcus furiosus* polymerase (Stratagene) and a Pharmacia thermal cycler according to the instructions of the manufacturer. The N-terminal oligonucleotide primer consisted of the sequence:

5'-CCAGGATGCTGAAGAAGCAGTCTGCA-3' (SEQ ID NO:1).

The C-terminal oligonucleotide primer consisted of the sequence:

5'-CCAGTCGACAGGTGCTAATTCCAGCTAG-3' (SEQ ID NO:2).

The amplification protocol consisted of an initial denaturing cycle of 8 minutes at 96°C, followed by a 1 minute annealing step at 65°C and finally a 4 minute polymerization cycle at 75°C. The amplification then switched to a 1 minute denaturation, 1 minute annealing and a 4 minute polymerization for 24 additional cycles.

#### *Example 4*

##### *Subcloning the Polymerase Chain Reaction (PCR)-Generated Fragments*

A fraction of the PCR fragments has a single adenosine nucleotide added at the 3' end because of the template-independent terminal transferase activity of *Pyrococcus furiosus* polymerase. This activity was exploited to clone the amplified DNA fragments with the efficiency of sticky end cloning. To do this, the pUC18 vector (into which the fragment would be linked) was prepared as follows. One µg Hind II-digested vector was incubated with 20 units of terminal transferase and 10 µM ddTTP in a final volume of 30 µl for 1 hour at 37°C. ddTTP was used to assure the incorporation of only one thymidine at the 3' ends of the blunt digested vector (Holton *et al.*, *Nucleic Acids Research* 19(5):1156 (1990)). The vector and the PCR fragments were purified using the Gene Clean™ kit from Pharmacia. The amplified GlcNAc Tr I coding fragment (200 ng) was finally ligated in the pUC18 vector (40 ng) at 12°C for 17 hours. The first part of the gene (MLKKQSAGLVWGAIFVAWNALLLFFWTRPAPGRPPSVS [SEQ ID NO:3]) which coded for secretion and for retention in the medial Golgi compartment was replaced with a nucleotide sequence coding for the "prepro"-secretion signal-sequence of the yeast mating factor. This nucleotide-sequence was isolated from the plasmid pSCGALIMF3 (Belgian Coordinated Collections of Microorganisms (BCCM) catalogue of the Laboratorium voor Moleculaire Biologie Plasmidencollectie (LMBP) culture collection at University Gent) after digestion with Stu I and Xba I restriction enzymes. (Materials listed as being



obtained from the LMBP are available to anyone who requests them). The yeast mating factor nucleotide sequence that was used is

ATG AGA TTT CCT TCA ATT TTT ACT GCA GTT TTA TTC GCA GCA TCC TCC  
MET Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser

GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA CAA  
Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln

ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA GGG GAT TTC  
Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe

GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG  
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu

TTT ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA  
Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val

TCT TTG GAT AAA AGG [Seq ID NO:4]  
Ser Leu Asp Lys Arg [Seq ID NO:5]

A map of plasmid pSCGAL1MF3 appears as Figure 3 and a more detailed description in Table 2.

To make plasmid pSCGAL1MF3, plasmid pSCGAL1MF2 (available from the LMBP collection) was opened with *AccI*, filled in with Klenow DNA polymerase and ligated. In this way, the *HindII* and *SalI* sites of the polylinker are lost, a *NruI* site in the polylinker is created, and the *HindII* site inside the prepro secretion signal of the  $\alpha$ -mating factor 1 becomes unique.

The blunt ended Stu I side was ligated to Eco 47III-digested GlcNAc Tr I in the pUC18 vector. The "prepro-GlcNAc Tr I" coding nucleotide sequence was then isolated from the pUC18 vector through an Eco RI, Hind III double digest. Subsequently, an Eco RI linker was ligated to the blunted Hind III site to allow insertion in the mammalian pCAGGS vector. Directional cloning was carried out with Xba I, Eco RI digested vector and fragment.

In this expression cassette, the first part of the gene that coded for the secretion and Golgi-retention signals, was replaced by a nucleotide sequence coding for the "prepro" secretion signal sequence of the yeast  $\alpha$ -mating factor (Burke *et al.*, *J. Biol. Chem.* 267:24433-24440 (1992); and Brake, A.J., in *Yeast Genetic Engineering* (Barr *et al.*, eds.), Butterworths Pub., Stoneham, MA (1989), pp. 269-280). The vector was called pCAMFhGNTIf1 (Figure 4). Its

construction is diagrammed in Figures 4A, 4B, 4C and 4D and it is described in more detail in Table 1. Essentially, the *XbaI-StuI* fragment of pSCGAL1MF3 (above), containing the prepro secretion signal of the  $\alpha$ -mating factor 1 gene, was ligated to the *XbaI-Eco47III* vector fragment of pUChGNTI. Because of the template-independent terminal transferase activity of *Pyrococcus furiosus* polymerase, a fraction of the PCR fragments has a single adenosine nucleotide added at the 3' end. We exploited this activity to clone the amplified DNA fragments with the efficiency of sticky end cloning. To do this, the acceptor pUC18 vector was prepared as follows: 1  $\mu$ g *Hind* II digested vector was incubated with 20 units terminal transferase and 10  $\mu$ M ddTTP in a final volume of 30  $\mu$ l for 1 hour at 37°C (Holton and Graham, 1990). The amplified GlcNAc Tr I coding fragment (200 ng) was ligated in the treated pUC18 (Norrander *et al.*, *Gene* 26:101-106 (1983) vector (40 ng) at 12°C for 17 hours. This intermediate construct was then digested with *Hind* III and *Eco* RI, the sticky ends were filled in with Klenow DNA polymerase and *Eco* RI linkers (5'-CGGAATTCCG-3') were added. Finally, this *Eco* RI-*Eco* RI fragment was digested with *Xba* I and *Eco* RI and the resulting *Xba* I-*Eco* RI fragment was inserted into the *Xba* I-*Eco* RI digested pCAGGS vector. This expression plasmid carries a fusion of the prepro secretion signal of the  $\alpha$ -mating factor 1 gene to the mature human gene encoding N-acetylglucosaminyltransferase I (GlcNAc Tr I), coded into the sense orientation relative to the chicken  $\beta$ -actin promoter that is preceded by the CMV-IE enhancer sequence. The nucleotide sequence of the human GlcNAc Tr I was obtained from EMBL Accession no. M55621.

After transient transfection of the vector to COS-7 cells (ATCC CRL-1651), the expressed GlcNAc Tr I enzyme was efficiently secreted in Dulbecco minimal medium (Dulbecco's modified eagle medium, Dulbecco, R. *et al.*, *Virol.* 8:396 (1959); Smith, J.D. *et al.*, *Virol.* 12:185 (1960); Tissue Culture Standards Comm., *In Vitro* 6:2 and 93 and *In Vitro* 9:6). The COS supernatant was concentrated about tenfold and was used in GlcNAc Tr I activity assays. GlcNAc Tr I is enzymatically well-characterized and uses a  $\text{Man}_3\text{GlcNAc}_2$  oligosaccharide as a preferred acceptor substrate (Nishikawa *et al.*, *J. Biol. Chem.* 263(17):8270-

8281 (1988)). In general, oligosaccharides with the common formula  $R1\alpha 1,6(\text{Man}\alpha 1,3\text{Man}\beta 1,4\text{GlcNAc}R2)$  are accepted as substrates for GlcNAc Tr I where R1 is one or more mannose residues linked through  $\alpha$  bonds; R2 may be  $\beta 1-4(\text{Fuc}\alpha 1-6)\text{GlcNAc-Asn-X}$ ,  $\beta 1-4\text{GlcNAc-Asn-X}$ ,  $\beta 1-4\text{GlcNAc}$  or H). A GlcNAc residue derived from UDP-GlcNAc was incorporated in the  $\beta 1-2$  linkage to the mannose residue linked  $\alpha-1,3$  to Man  $\beta 1,4\text{GlcNAc}R2$  (Schachter, H., *Glycobiology* 1(5):453-461 (1991)).

### Example 5

#### The GlcNAc Tr I Assay

The mammalian vector pCAGGS and "prepro-GlcNAc Tr I" coding sequences (pCAMFhGNTIf1) were transfected into COS cells according to the protocol of McCutchan *et al.* (*J. Nat. Cancer Inst.* 41:351-357 (1968)). GlcNAc Tr I was secreted in Dulbecco minimal medium without serum. The enzyme was concentrated by ultrafiltration in Centricon-30™ centrifugal microconcentrators (Amicon).

GlcNAc Tr I activity was assayed according to a method described by Nishikawa *et al.* (*J. Biol. Chem.* 263(17):8270-8281 (1988)) as follows. In a total volume of 0.030 ml, the following were added: 0.33 mM Man<sub>5</sub>Gn; 0.1 M 2-[N-morpholino]ethanesulfonic acid (MES) (pH 6.1); 20 mM MnCl<sub>2</sub>; 5 mM AMP (as pyrophosphatase inhibitor); 0.1 M GlcNAc (as  $\beta$ -N-acetylhexose-aminidase inhibitor); 0.34 mmol UDP-(<sup>14</sup>C)GlcNAc (Amersham); and 10  $\mu$ l concentrated COS supernatant. Incubation was at 37°C for 1 to 4 hours. The proteins were then separated from the oligosaccharides through precipitation by the addition of 100% ice-cold ethanol to a final concentration of 66%.

Oligosaccharides were separated on silica 60 high-performance thin-layer plates using a solvent containing butanol/acetic acid/water (20:10:10; v/v/v). The plates were developed twice in the same solvent (Vauhkonen *et al.*, *Eur. J.*

*Biochem. 152:43-50 (1985)*). Radioactive oligosaccharides were visualized after exposure of the TLC plate to an X-ray film for several days.

Oligosaccharides were also visualized by orcinol staining as follows. A mixture of 0.6% orcinol in 10% sulfuric acid and 0.1% Fe(III)Cl<sub>2</sub> was sprayed on top of the TLC plate which was subsequently heated to 100°C for 10 to 15 minutes.

Instead of oligosaccharides, where noted, glycoproteins were added to the reaction mixture for GlcNAc Tr I. About 10 µg glycoprotein (e.g. ovalbumin) was added to the 30 µl reaction mixture. Incubation at 37°C was over a period of 6 to 18 hours. The incorporation of radioactive GlcNAc into the oligosaccharide units on the proteins, separated on a SDS-polyacrylamide gel (Laemmli, U.K., *Nature* 227:680-685 (1970)), was visualized by autoradiography.

### *Example 6*

#### *Galactosyltransferase and Sialyltransferase Processing*

Additional *in vitro* modifications of N-acetylglucosamine-bearing glycoproteins or oligosaccharides were carried out with β-1,4 galactosyl transferase from human milk and α-2,6 sialyltransferase from rat liver. Both enzymes were obtained from Boehringer Mannheim.

Before carrying out these processing steps, CBH I was purified from the GlcNAc Tr I reaction mixture. A description for the purification of this protein is available from Shoemaker *et al.*, *Bio/Technology* 1:687-690 (1993). Briefly, the COS cell medium was passed over a DEAE-sepharose column that had been equilibrated in 50 mM sodium-acetate buffer, pH 5. Cellulases (or CBH I alone) from *T. reesei* in a reaction mixture for GlcNAc Tr I treatment, were dialyzed to 50 mM sodium acetate buffer, pH 5. Then, they were separated from COS supernatant proteins through purification on a DEAE Sepharose® column (volume: 0.5 ml, about 1 cm in height, 0.5 cm diameter, fast flow resin, Pharmacia). Under these conditions, CBH I was retained.

A salt gradient (changing the NaCl concentration from 0-to 0.1 M in 400  $\mu$ l sodium acetate buffer, pH 5) removed a substantial part of the proteins present in the reaction mixture for the *in vitro* glycosylations, and CBH I was retained on the column. The salt concentration was further raised to 0.2 M (in 800  $\mu$ l), and CBH I eluted at 0.15 M NaCl or higher. The salt concentration was further raised to 0.5M (by applying 800  $\mu$ l) in order to elute as much of the CBH I from the column as possible. The CBH I-containing fractions were pooled and were dialyzed against a 50 mM Tris buffer, pH 8, and concentrated about 10-fold, using a Centricon ultracentrifugation device (Amicon). CBH I was then added to the reaction mixture for galactosyltransferase:  $\beta$ -1,4 galactosyl transferase required a pH of 8-8.5 and the presence of manganese for optimal specific activity (Schanbacher *et al.*, *J. Biol. Chem.* 245:5057-5061 (1970); Yoon *et al.*, *Glycobiology* 2:161-168 (1992)). To the GlcNAc Tr I-treated proteins or oligosaccharides were added: 0.17  $\mu$ mol UDP ( $^{14}$ C)Gal (285 mCi/mmol) or "cold" UDP-Gal; 2 milliunits galactosyltransferase; and  $MnCl_2$  to a final concentration of 20 mM in a final volume of 0.030 ml. Galactosylation was carried out at 37°C for about 8 hours.

$\alpha$ -2,6 Sialyltransferase required a pH of 6-6.5 for optimal activity (Weinstein *et al.*, *J. Biol. Chem.* 257:13845-13853 (1982)). To the galactosyltransferase-reaction mixture, the following were added: 0.18  $\mu$ mol CMP ( $^{14}$ C)NANA (281 mCi/mmol) (Amersham) to a final concentration of 6 mM; 2 milliunits  $\alpha$ -2,6 sialyltransferase; and NaCl (to stabilize the sialyltransferase, final concentration: 50 mM). The pH was adjusted to 6-6.5 through the addition of 1M MES. The final volume of the reaction mixture was 0.050 ml. The reaction mixture was incubated at 37°C for 8 hours. The incorporation of radioactive sugar-residues on glycoproteins was visualized as described above.

*In vitro* modifications of glycosylated ribonuclease B, obtained from Oxford Glycosystems, were also performed. The glycosylated ribonuclease B was incubated with GlcNAc Tr I as described in Example 5. The resulting oligosaccharide product is shown in Figure 12, lane 1. The resulting product was

incubated with galactosyl transferase:  $\beta$ -1,4 galactosyl transferase as described above to produce \*Gal linked to GlcNAc on Man<sub>5</sub>GlcNAc<sub>2</sub> as shown in Figure 12, lane 2. This product was incubated with  $\alpha$ -2,6 sialyltransferase as described above to produce sialic acid linked to \*Gal linked to \*GlcNAc on commercial Man<sub>5</sub>GlcNAc<sub>2</sub> as shown in Figure 12, line 3.

The use of N-glycans, liberated from ribonuclease B, as acceptor substrates for GlcNAc Tr I, galactosyltransferase, and  $\alpha$ -2,6 sialyltransferase was also studied. The N-glycans were liberated as described in Example 2. Following liberation from the protein, two GlcNAc-accepting structures are available. Therefore, a more complex glycosylation pattern is observed following sequential reaction with GlcNAc Tr I, galactosyltransferase, and  $\alpha$ -2,6 sialyltransferase, as depicted in Figure 12, lanes 4-6. However, the expected hybrid and complex structure were observed.

#### *Example 7*

##### *Improvement of Hybrid Glycoprotein Structures with $\alpha$ -1,2 Mannosidase*

Glycoproteins (up to 100 mg) or oligosaccharides (prepared from about 100 mg of protein) were treated with 2 to 6  $\mu$ units *A. saitoi*  $\alpha$ -1,2 mannosidase (Oxford Glycosystems) in 100 mM sodium-acetate (pH 5) for 18 hours at 37°C. Glycoproteins were dialyzed to 20 mM MES, pH 6.1, before further processing with GlcNAc Tr I. Incorporation of radioactive GlcNAc on oligosaccharides was visualized on X-ray film after separation through TLC. Radioactive signals originating from (<sup>14</sup>C)GlcNAc-residues on proteins were visualized as described above.

### Example 8

#### *Mannosidase and Mannosyltransferase Assays*

Mannosidase activity was assayed in the extracellular medium from *T. reesei* and *Aspergillus saitoi*. *T. reesei* RUTC 30 was grown in minimal medium, according to Uusitalo *et al.* (1991) with 2% lactose as a carbon source. The same medium, supplemented with 2% glucose was used in parallel in order to determine whether there is an influence of different carbon sources on expression of mannosidases. *Aspergillus saitoi* was grown on minimal medium according to Czapek (Onions and Pitt, Appendix: Media. In Hawksworth, D.L. and Kirsop, B.E., (Eds.), Living resources for biotechnology. Cambridge University Press, Cambridge, UK, pp. 180-199, 1988) with 1% yeast extract and, in parallel 2% glucose as the carbon sources. After 4 days fermentation at 28°C, fungal cells were separated from growth medium by filtration over a GF/F glass microfiber filter (Whatman).

The growth medium was further concentrated (70 fold), using centriprep and centricon ultracentrifugation devices (M.W. cut off: 10 kD; Amicon). Reaction mixtures for assaying mannosidase activities contained in a volume of 20 µl: 500 ng ANTS labelled high mannose oligosaccharides from ribonuclease B (Oxford Glycosystems); Sodium cacodylate pH 6.1 (60 mM final concentration); CaCl<sub>2</sub> (20 mM) and 15 µl concentrated growth medium. Incubation of the reaction mixtures was overnight at 37°C. Oligosaccharides were then separated on a polyacrylamide gel as described.

The collected fungal cells were used for preparation of crude extracts: after washing with 50 mM sodium cacodylate buffer, the dry cell pellet was ground in a mortar using liquid nitrogen. Broken cells were transferred to ice cold sodium cacodylate buffer (50 mM, pH 6.1) containing MgCl<sub>2</sub> (15 mM) and a cocktail of protease inhibitors (PMSF, leupeptin, benzamidin, aprotinin in concentrations prescribed by the manufacturer (Boehringer Mannheim). Cells were left in buffer on ice for 30 minutes. We used differential centrifugation to

obtain 15000g, 40000g and 100000g membrane pellets. Finally Triton X 100 (2% final concentration) was added to solubilize enzymes from the membranes. Reaction mixtures for assaying mannosidases were prepared as already described. Reaction mixtures for assaying mannosyltransferases contained in a volume of 20  $\mu$ l: 100 ng ANTS labelled Man<sub>5</sub>GlcNAc; 10  $\mu$ g UDP-mannose; MnCl<sub>2</sub> (20 mM final concentration) and 10  $\mu$ l of the 100000g membrane preparation. The reaction mixtures were incubated for 4 hours at 37°C.

### Example 9

#### *Glycoproteins as Acceptor Substrates for GlcNAc Tr I*

Different glycoproteins were used in GlcNAc Tr I activity assays to determine whether they were carrying glycosyl structures that were substrates for GlcNAc Tr I. Ovalbumin, which was used as a positive control in this experiment, has two candidate glycosylation sites, but only one site is actually glycosylated. A fraction of the oligosaccharides that are present on ovalbumin is Man<sub>5</sub>Gn<sub>2</sub> (Tai *et al.*, *J. Biol. Chem.* 252:6687-6694 (1977)). As negative controls, *S. cerevisiae* invertase and human transferrin were used. Invertase from *S. cerevisiae* carries high mannose oligosaccharides with Man<sub>5</sub>Gn<sub>2</sub> being the smallest structure formed (Trimble *et al.*, *J. Biol. Chem.* 261:9815-9824 (1986)). Transferrin, a human glycoprotein, has two complex-type N-glycans (März *et al.*, *Can. J. Biochem.* 60:624-630 (1982)). Most transferrin oligosaccharides are bi-antennar with sialic acid as terminal sugar-residues.

Proteins secreted from the *T. reesei* mutant strain RUTC 30 and cellulases from an unknown strain of *T. reesei* (commercial source; Fluka, Buchs, Switzerland) were studied. *T. reesei* mutant strain RUTC 30 has an increased capacity to secrete proteins (Ghosh *et al.*, in *Trichoderma reesei Cellulases: Biochemistry, Genetics, Physiology & Application* (Kubicek *et al.*, eds.), Royal Soc. of Chemistry, Cambridge, England (1990), pp. 115-138). The results (Figure 5) show that radioactive (<sup>14</sup>C)GlcNAc was transferred from UDP-(<sup>14</sup>C)GlcNAc



to oligosaccharides on ovalbumin and on extracellular secreted proteins from both *T. reesei* strains. These results indicated the presence of trimming enzymes in *T. reesei* which were capable of the *in vivo* formation of acceptor-oligosaccharides for GlcNAc Tr I.

In addition, the use of other proteins as acceptor substrates for GlcNAc Tr I was studied. The presence of a substrate for GlcNAc Tr I was determined using the GlcNAc Tr I assay described above in Example 5 by measuring the incorporation of radioactive GlcNAc into the glycoprotein by autoradiography of 12.5% SDS-PAGE gels. Incorporation of radiolabelled GlcNAc was demonstrated for  $\alpha$ -amylase from *Aspergillus oryzae*, obtained from Fluka, Buchs, Switzerland;  $\alpha$ -amylase from *Aspergillus niger*, also obtained from Fluka; and for proteins in a commercial  $\beta$ -galactosidase preparation from *Aspergillus oryzae*, obtained from Sigma, St. Louis, MO, USA. See Figure 11. Incorporation of radiolabelled GlcNAc was also demonstrated for papain digested cellobiohydrolase I from *Trichoderma reesei* RUTC 30. Following papain digestion, cellobiohydrolase I no longer contains the C-terminal end of the enzyme which is heavily O-glycosylated. Van Tilbeurgh *et al.*, FEBS Lett. 204:223-227 (1986).

#### **Example 10**

##### ***Free Oligosaccharides as Acceptor Substrate for GlcNAc Tr I***

The oligosaccharides from *Trichoderma* extracellular glycoproteins were isolated to further evaluate and confirm that Man<sub>5</sub>GlcNAc<sub>2</sub> was the GlcNAc accepting N-glycan. Oligosaccharides were enzymatically removed with N-glycanase. This enzyme releases all types of N-linked sugar chains through cleavage of the glycosylamine linkage to asparagine residues (Tarentino *et al.*, *Biochemistry* 24:4665-4671 (1985)). The oligosaccharides were then tested in a reaction mixture containing GlcNAc Tr I. A commercial mixture of oligosaccharides ranging from Man<sub>5</sub>GlcNAc<sub>2</sub> to Man<sub>7</sub>GlcNAc<sub>4</sub> obtained from

ribonuclease B through hydrazinolysis (Oxford GlycoSystems No. RP-2500) were used as a positive control for this experiment (Liang *et al.*, *J. Biochem.* 88:51-58 (1980)). Oligosaccharides that had been enzymatically released from *S. cerevisiae* invertase were used as negative controls. GlcNAc Tr I transferred radioactive GlcNAc from UDP-( $^{14}\text{C}$ )GlcNAc to fungal  $\text{Man}_3\text{GlcNAc}_2$  glycans. This was detected after separation of the manipulated oligosaccharides through thin layer chromatography (TLC). The position of the labelled fungal oligosaccharides, as revealed by autoradiography (Figure 6), coincided with that of the positive control. With the *T. reesei* mutant strain RUTC 30 an additional oligosaccharide structure that was larger than  $\text{Man}_3\text{GlcNAc}_2$  also acted as an acceptor for GlcNAc Tr I. This indicated the existence of differences in glycosylation patterns at the strain level.

### Example 11

#### *Galactosyltransferase and Sialyltransferase Assays*

Additional *in vitro* modifications of GlcNAc-bearing glycoproteins or oligosaccharides were carried out with the commercial  $\beta$ -1,4 galactosyl transferase (Boehringer Mannheim) from human milk (Schanbacher *et al.*, *J. Biol. Chem.* 245:5057-5061 (1970)) and commercial  $\alpha$ -2,6 sialyltransferase (Boehringer Mannheim) from rat liver (Weinstein *et al.*, *J. Biol. Chem.* 257:13845-13853 (1982)). Galactosylation was demonstrated through the incorporation of radioactive galactose on *in vitro* synthesized, non-labelled, GlcNAc-bearing glycosylstructures. The completion of the synthetic pathway was demonstrated through the incorporation of radioactive sialic acid on "cold" galactose that was added in a  $\beta$ -1,4 linkage to GlcNAc. Glycoproteins labelled in this manner were separated through electrophoresis on a SDS-polyacrylamide gel. During electrophoresis, sialylated glycoproteins moved slower compared to non-sialylated proteins. This was observed as a shift of the sialylated proteins towards higher

molecular weights. To clearly demonstrate this effect, one *Trichoderma* protein, namely cellobiohydrolase I (CBH I), was examined in particular.

After the GlcNAc Tr I processing step, CBH I was purified from the COS supernatant-containing reaction mixture by ion-exchange chromatography on DEAE Sepharose (Shoemaker *et al.*, *Bio/Technology* 1:687-690 (1983)). The purification step avoided any potential interference by COS supernatant proteins, which also can be an acceptor for sialyltransferase.

An autoradiogram was obtained with CBH I-containing radioactive GlcNAc versus radioactive sialylated CBH I (Figure 7). A clean shift in the electrophoretic mobility of the sialylated CBH I as compared to the GlcNAc-containing form was shown. This demonstrated that it was possible to modify the naturally occurring glycosylstructures on *Trichoderma* CBH I into hybrid structures with terminal sialic acid residues. The two final modification steps were confirmed on the free oligosaccharides. The incorporation of galactose followed by the incorporation of sialic acid, always caused a shift in the molecular weight of the oligosaccharide molecules. This was observed as shifts in the mobility of the differently manipulated oligosaccharides in TLC.

### *Example 12*

#### *Improvement of Hybrid Glycoprotein Structure Through the Use of $\alpha$ -1,2 Mannosidase*

When using a fungus such as *T. reesei* to produce heterologous, therapeutically valuable proteins, a substantial fraction of the high mannose oligosaccharides will not be an acceptor for GlcNAc Tr I. On the other hand, in mammalian cells, an  $\alpha$ -1,2 mannosidase that is present in the cis-compartment of the Golgi apparatus trims most, if not all, high mannose structures to Man<sub>3</sub>GlcNAc<sub>2</sub> and thus assures that carbohydrate chains are convertible to the complex type (Tulsiani *et al.*, *J. Biol. Chem.* 263:5408-5417 (1988)).

A commercial  $\alpha$ -1,2 mannosidase (Oxford Glycosystems, Oxford, UK) from *A. saitoi* (Yamashita *et al.*, *Biochem. Biophys. Res. Comm.* 96:1335-1342

(1980)) was used to investigate to what extent glycosylation processing resembled that of mammalian cells. The effect of preincubation of fungal oligosaccharides or glycoproteins with  $\alpha$ -1,2 mannosidase on the *in vitro* incorporation of GlcNAc in a GlcNAc Tr I assay was determined.

Oligosaccharides from bovine ribonuclease B, from *T. reesei* extracellular proteins were treated with *A. saitoi*  $\alpha$ -1,2 mannosidase. Treated and non-treated N-glycans were processed and visualized by fluorophore labelling of reducing saccharides (Figure 8). In this method, the reducing end of saccharides, liberated as described above, was reacted with 8-aminonaphthalene-1,3,6-trisulfonic acid (ANTS), as described by Jackson, P., "Methods in Enzymology. Guide to techniques in Glycobiology", Vol. 230, p. 250-265, Eds. Lennartz, W. & Hart, G. (1994)). Basically, 10  $\mu$ l of 0.15 M ANTS in acetic acid-water solution (3:17 v/v) and 10  $\mu$ l of 1 M sodium cyanoborohydride, dissolved in DMSO were added to lyophilized oligosaccharides, enzymatically released from 400  $\mu$ g glycoprotein or to 5  $\mu$ g of bovine ribonuclease B oligosaccharides, commercially obtained from Oxford Glycosystems. No prior purification of oligosaccharides on a Biogel P2 column was necessary. After overnight incubation at 37°C, ANTS labelled oligosaccharides were precipitated through addition of 4 volumes of ice cold acetone (at minus 20°C). The oligosaccharides were pelleted through centrifugation (for 4 minutes at 10,000 x g). Unreacted ANTS in the acetone containing supernatant was removed. Oligosaccharides were redissolved in a suitable volume of glycerol:water (1:4 v/v) and stored at minus 70°C. ANTS derivatized oligosaccharides were separated on a 30% acrylamide, 0.8% N,N'-methylene-bisacrylamide gel (on the SE 250 Mighty Small II electrophoretic apparatus, that is also used for separation of proteins through PAGE). In order to obtain "crystal clear" gels, the gel solution was poured between plastic sheets that were adhered to the mold plates with water. Stacking of the oligosaccharides was allowed at a current of 15 mA for 30 minutes, while separation happened at a current of 30 mA for 2.5 hours. As a reference standard, a glucose ladder was loaded, obtained after digestion of wheat starch (described by Jackson, P.,

"Methods in Enzymology. Guide to techniques in Glycobiology", Vol. 230, p. 250-265, Eds. Lennartz, W. & Hart, G. (1994)). The electrophoretic band patterns were viewed on a UV transilluminator and photographed through a red filter (Cokin A. 003; Cromofilter SA, Paris, France), using standard black-and-white film. A polaroid type 667 film with a speed of ISO3000 and an aperture of 4.5 required an 8 sec exposure (Figure 8).

The oligomannose-type N-glycans from ribonuclease B, ranging from  $\text{Man}_5\text{GlcNAc}_2$  to  $\text{Man}_7\text{GlcNAc}_2$ , were all converted to  $\text{Man}_7\text{GlcNAc}_6$ . This agreed with the fact that the biosynthesis of N-linked sugar chains on ribonuclease B is known to be arrested at an intermediary stage of processing, as demonstrated by the fact that high mannose structures had not all been converted to  $\text{Man}_5\text{GlcNAc}_2$  and had extra mannose residues only in the  $\alpha$ -1,2 linkage. Oligosaccharides which had been isolated from a mixture of proteins secreted from *T. reesei* were partly converted to  $\text{Man}_5\text{GlcNAc}_2$ , whereas a substantial part of the oligosaccharide pool was not converted. From the starting material, a fraction of the oligosaccharides seemed to be smaller than  $\text{Man}_5\text{GlcNAc}_2$ , while another fraction was larger than  $\text{Man}_5\text{GlcNAc}_2$ . In Fig. 8, only trimming of *T. reesei* oligosaccharides is shown.

The fungal oligosaccharides that had been treated with *A. saitoi*  $\alpha$ -1,2 mannosidase were then added to a reaction mixture for GlcNAc Tr I. The oligosaccharides were analyzed by thin layer chromatography.  $\alpha$ -1,2 Mannosidase treatment *in vitro* favored the formation of acceptor substrate for GlcNAc Tr I (Figure 9) because much more radioactive GlcNAc was incorporated into the fungal oligosaccharides. A small fraction of the *S. cerevisiae* invertase oligosaccharides was also trimmed to the GlcNAc-accepting high mannose structure.  $\text{Man}_5\text{GlcNAc}_2$  glycans isolated from ovalbumin were the positive control for this experiment. On the autoradiogram, the position of the labelled fungal oligosaccharides coincided with that of the positive control. This confirmed the formation of  $\text{GlcNAcMan}_5\text{GlcNAc}_2$  in the different reaction mixtures.

With the RUTC 30 *Trichoderma* strain,  $\alpha$ -1,2 mannosidase treatment also gave rise to more of a second, larger GlcNAc-accepting oligosaccharide. When the mannosidase treatment was repeated on intact glycoproteins (Figure 10) the results were analogous with those obtained with free oligosaccharides. That is, more labelled GlcNAc was transferred to ovalbumin and to *T. reesei* glycoproteins when they were first pretreated with  $\alpha$ -1,2 mannosidase. GlcNAc now was also transferred to *S. cerevisiae* invertase.

In summary, the method of the invention allows the production of mammalian-like, hybrid oligosaccharides on glycoproteins secreted from the filamentous fungus *T. reesei* and its mutant strain *T. reesei* RUTC 30. The *in vitro* experiments used the following mammalian glycosyltransferases: human GlcNAc Tr I produced in COS cells;  $\beta$ -1,4 galactosyl transferase from human milk and  $\alpha$ -2,6 sialyltransferase from rat liver. Preincubation with  $\alpha$ -1,2 mannosidase from *A. saitoi* substantially improved GlcNAc incorporation into the fungal proteins. This embodiment obtained a fungus that synthesized oligosaccharides that were convertible to complex mammalian-type structures in the simplest possible way. Since the first steps of the complex carbohydrate synthetic pathway were executed *in vivo* in a fungus such as *Trichoderma*, completion of the glycosylation pathway was possible through *in vitro* enzymatic oligosaccharide synthesis and modification. As a result of this invention, large scale stereo-controlled oligosaccharide synthesis will be possible in the future (Ichikawa *et al.*, *Anal. Biochem.* 202:215-238 (1992)). The fact that a fungus can be manipulated to construct well-defined and uniform glycosyl structures on its secreted proteins offers possibilities to investigate the biological significance of oligosaccharide diversity and to perform carbohydrate engineering. For certain proteins, the production of a single glycoform may be produced to obtain a uniform therapeutic profile (Stanley, P., *Molecular and Cellular Biology* 9:377-383 (1989)).

### Example 13

#### *Analysis of the N-glycan Profile of T. reesei Glycoproteins by Fluorophore Labelling*

A detailed image, both quantitatively and qualitatively, was obtained when oligosaccharides were derivatized with the fluorophore 8-aminonaphthalene-1,3,6 trisulphonate and subsequently electrophoretically separated on a polyacrylamide gel. In Figure 4, we demonstrate the oligosaccharide pattern from *T. reesei* RUTC 30 cellobiohydrolase I, purified after fermentation in minimal medium (Nyyssönen *et al.*, *Bio/Technology* 11:591-595 (1993)). The pattern obtained with a mixture of proteins secreted by the same *Trichoderma* strain, but in a different growth medium (according to Uusitalo *et al.*, 1991) is also shown. Only a minor fraction of oligosaccharides from the starting material seems to be  $\text{Man}_3\text{GlcNAc}_2$ . More abundant are  $\text{Man}_6\text{GlcNAc}_2$ ,  $\text{Man}_7\text{GlcNAc}_2$ ,  $\text{Man}_8\text{GlcNAc}_2$  and  $\text{Man}_9\text{GlcNAc}_2$  oligosaccharides. N-glycans larger than  $\text{Man}_9\text{GlcNAc}_2$  were also found.

With pure CBH I, oligosaccharides even smaller than  $\text{Man}_3\text{GlcNAc}_2$  were isolated. In general, the *Trichoderma* sugar chains are clearly much smaller than those isolated from *Saccharomyces cerevisiae* glycoproteins. Since  $\alpha$ -1,2 mannosidase trimming is incomplete (Figure 8), it is very likely that mannose residues are present in linkages different from the  $\alpha$ -1,2 linkage due to transfer to trimming products by one or more mannosyl transferases.

### Example 14

#### *Determination of T. reesei Mannosidase and Mannosyltransferase Activities and Conclusions*

In order to investigate further in detail the resemblance between *T. reesei* glycosyl synthesis and the mammalian system, we tried to localize the mannosidase activity responsible for the oligosaccharide panel on the secreted fungal proteins. First, we checked whether mannosidases were present in the extracellular medium

of the fungus, which could eventually be responsible for "postsecretional" trimming of the oligosaccharides on other secreted proteins. We developed an assay to determine this activity as follows: oligosaccharides from bovine ribonuclease B (commercially available as a reference panel from Oxford Glycosystems) were used as substrate for mannosidases. A complete conversion to  $\text{Man}_5\text{GlcNAc}_2$  is obtained if enough  $\alpha$ -1,2 mannosidase is present.  $\text{Man}_5\text{GlcNAc}_2$  is further trimmed if  $\alpha$ -1,3 and/or  $\alpha$ -1,6 mannosidases are present. After labelling with ANTS, the ribonuclease B reference oligosaccharides were added to 70-fold concentrated extracellular medium from a four day old *T. reesei* culture (with fungal cells removed). A four day old, concentrated culture supernatant from *Aspergillus saitoi* was used as a positive control for this assay: it is known that the latter organism secretes different mannosidases (an  $\alpha$ -1,2 and  $\alpha$ -1,3(6) mannosidase) when grown on minimal medium containing mannan as the carbon source (Keskar, S.S. *et al.*, *Biotechnology Letters* 15:695-690 (1993)). In Figure 7, we demonstrate the result of an overnight incubation of the reaction mixtures: the  $\alpha$ -1,2 mannosidase activity from *A. saitoi* is clearly detectable. Most ribonuclease B oligosaccharides are trimmed to  $\text{Man}_5\text{GlcNAc}_2$ . No or only marginal quantities of mannosidase are present in the medium of *T. reesei*, since the ribonuclease reference panel remained untouched. We mention here that *T. reesei* secreted many more proteins in its minimal medium (about 300  $\mu\text{g/ml}$ ) than did *A. saitoi* (barely detectable, using the Bradford assay).

Using the same ANTS labelled oligosaccharide panel from ribonuclease B, we found intracellular mannosidase activity in crude extracts from *T. reesei*, *A. saitoi*, L929 mouse cells and from *S. cerevisiae*. We further tried to discriminate mainly between mannosidases, active in glycosylation processing in the endoplasmic reticulum, the Golgi apparatus and those active in vacuoles. Using differential centrifugation or sucrose gradients to separate organelles, prepared from *T. reesei* cells, we did not obtain sufficient resolution of different mannosidase activities in different organelles. However,  $\alpha$ -1,2 mannosidase activity was abundantly present in fractions that were enriched for



mannosyltransferase activity. Determination of the mannosyltransferase activity was done after adaptation of the assay, described by Nakajima and Ballou (*Proc. Natl. Acad. Sci. USA* 72:3912-3916 (1975)). With reaction mixtures containing UDP-mannose as sugar-donor, ANTS labelled  $\text{Man}_4\text{GlcNAc}$  as a substrate and glycosylation enzymes solubilized from the membrane preparations by Triton X 100, mannosyltransferase activity was demonstrated by retardation in the electrophoretic mobility of the substrate oligosaccharides (results not shown).

The examples above demonstrate that it is possible to construct mammalian-like, hybrid oligosaccharides on glycoproteins secreted from the filamentous fungus *Trichoderma reesei*. Mammalian glycosyltransferases, namely human N-acetylglucosaminyl transferase I produced in COS cells,  $\beta$ -1,4 galactosyl transferase from human milk, and  $\alpha$ -2,6 sialyltransferase from rat liver, were used to mimic *in vitro* the glycosylation synthesis pathway as it occurs in mammalian cells. Preincubation with  $\alpha$ -1,2 mannosidase from *Aspergillus saitoi* substantially improved GlcNAc incorporation on the fungal proteins. With free N-glycans isolated from *Trichoderma reesei* cellulases, it was demonstrated that not all sugar chains are convertible to the ideal acceptor substrate for GlcNAc Tr I:  $\text{Man}_3\text{GlcNAc}_2$ . The majority of the N-linked oligosaccharides resemble the high mannose structures present on certain proteins from mammalian cells, ranging predominantly from  $\text{Man}_3\text{GlcNAc}_2$  to  $\text{Man}_5\text{GlcNAc}_2$ . With pure CBH I, obtained after fermentation in *Trichoderma* minimal medium (Nyyssönen *et al.*, 1993) a substantial fraction of the oligosaccharides seems to be even smaller than  $\text{Man}_3\text{GlcNAc}_2$ . Using another fermentation medium, we now also obtained oligosaccharides larger than  $\text{Man}_3\text{GlcNAc}_2$ . The electrophoretic mobility of CBH I produced in the different media also changed notably. After deglycosylation, CBH I produced as described by Nyyssönen *et al.*, (1993) shifted only slightly compared to the original form after electrophoretic separation on a polyacrylamide gel. Exhaustive digestion (long incubation time and many units N-glycanase) was needed to liberate oligosaccharides. With the growth conditions we used, CBH I was easily deglycosylated, giving rise to a pronounced electrophoretic shift

compared to the original protein (results not shown). The effects, environmental factors can have on protein glycosylation are profoundly described by Goochee and Monica (*Bio/Technology* 8:421-427 (1990), *Bio/Technology* 9:1347-1355 (1991)). Their reviews strengthen our belief that the growth medium can be the cause of the differences in glycosyl patterns found on *Trichoderma* proteins.

From the experiments we conducted to elucidate the localization of the mannosidase(s) responsible for the small N-glycans on *Trichoderma* secreted proteins. The possibility of secretion of mannosidases that could act on the other secreted fungal proteins seems very unlikely. Even with very concentrated growth medium and after a long incubation time, no trimming at all of substrate oligosaccharides occurred.

We presume that processing in the *Trichoderma* Golgi apparatus resembles partly that of mammalian cells and partly that of yeast: Mannosidases capable of trimming back the *Trichoderma* N-glycans to  $\text{Man}_3\text{GlcNAc}_2$  seem to be present. On the other hand, mannosyltransferases capable of transferring mannose residues in linkages different from the  $\alpha$ -1,2 linkage, are also present. The latter conclusion was confirmed after carrying out mannosyltransferase assays, analogous to the one described by Nakajima and Ballou (1973): using ANTS labelled  $\text{Man}_3\text{GlcNAc}$  as a substrate, we managed to demonstrate incorporation of up to two mannose residues. On the other hand,  $\text{Man}_3\text{GlcNAc}$  was no substrate for mannosyl transferases. Hence, we wonder if  $\text{Man}_3\text{GlcNAc}_2$ , the crucial structure for synthesis of complex sugar structures, will not be a substrate for mannosyl transferase(s) "in vivo" in *T. reesei*.

It is not yet known how similar glycosylation synthesis in *Trichoderma reesei* proceeds to that in mammalian cells. Therefore it is difficult to evaluate whether this organism can be easily manipulated to have more, if not all, of the glycosyl groups converted to mammalian-like structures. The *in vitro* experiments are an introductory, first step to manipulation of this fungus, so that it synthesizes oligosaccharides that are convertible to complex structures in the simplest possible way. If the first steps of the complex carbohydrate synthesis pathway would

occur *in vivo* in a fungus, such as *Trichoderma*, completion of the glycosylation pathway could be carried out by *in vitro* enzymatic oligosaccharide modification on proteins. We believe that large scale, stereo-controlled oligosaccharide synthesis will be possible in the future: much research is in progress to reduce the high expenses associated with these *in vitro* processing steps (Ichikawa *et al.*, 1992). Finally, another important aspect concerning this research can be mentioned: the fact that a fungus can be manipulated to synthesize well-defined and uniform glycosyl structures on its secreted proteins. For certain proteins, the production of single glycoform may be desired to obtain an uniform therapeutic profile.

### ***Example 15***

#### ***Transformation of *T. reesei* with GlcNAc Tr I coding sequences and Expression of Modified Glycoprotein from the *Trichoderma* Host***

A DNA vector is constructed that contains the coding sequence of human GlcNAc Tr I (Genbank Accession No. M55621; EMBL ID No. HSGLCNAC) as described above, and such that the DNA providing coding sequence for the GlcNAc Tr I enzyme is operably linked to the CBHI promoter and terminator. Such vector is transformed into *T. reesei*, using the technique described in EP 244,234, and positive transformants selected.

One of the positive transformants is further transformed with a second vector, encoding ovalbumin in a form that was secreted from the *Trichoderma* host, and transformants were selected that expressed both GlcNAc Tr I and ovalbumin.

Ovalbumin that is secreted into the *Trichoderma* medium is already processed to a first hybrid form by the intracellular action of GlcNAc Tr I. This ovalbumin is further processed using  $\beta$ -1,4-galactosyltransferase and  $\alpha$ -2,6-sialyltransferase as described in Example 11.

### ***Example 16***

#### ***Transformation of *T. reesei* with GlcNAc Tr I coding sequences and Expression of Modified Glycoprotein from the *Trichoderma Host****

As in Example 15, except that the ovalbumin is processed with non-specific  $\alpha$ -mannosidase after treatment with  $\beta$ -1,4-galactosyl transferase, or after treatment with  $\alpha$ -2,6-sialyltransferase.

### ***Example 17***

#### ***Transformation of *T. reesei* with GlcNAc Tr I coding sequences and Expression of Modified Glycoprotein from the *Trichoderma Host****

As in Example 15 or Example 16, except that the gene of interest encodes erythropoietin (EPO), human choriogonadotropin (HCG), follitropin (FSH), thyrotropin (TSH), lutropin (LH) NCAM, tenascin, thrombospondin, fibronectin, hormones, cytokines, interleukin-4, interferon gamma, growth factors, plasma proteins, coagulation factors, soluble receptors, an antibody, granulocyte-macrophage colony stimulating factor (GM-CSF), vascular endothelial growth factor, HIV virus glycoprotein gp120, viral coat proteins, immunoglobulin D, antithrombin III $\beta$ , plasminogen, von Willebrand factor, fibrinogen, corticosteroid-binding globulin, thyroxine-binding globulin, folate-binding protein, fibrinectin, bone and platelet osteonectin, EGF receptor, insulin and insulin-like growth factor-I receptors, basic fibroblast growth factor receptor, lymphocyte CD2, MHC Class II molecules, glucose transporters, erythrocyte band 3 protein,  $\beta$ -2 adrenergic receptors, transferrin receptor, VIP receptor, membrane class I MHC protein, vasopressin receptor of LLC-PK1 cells, low density lipoprotein receptor, asialoglycoprotein receptor, CD4 protein, thyrotropin receptor, PDGF receptor, jack bean concanavalin A, cobra venom factor, lactotransferrin, spinach chloroplast coupling factor, submaxillary gland mucin, intestinal brush border lactase-phlorizin hydrolase, arctic fish antifreeze glycoprotein, LDL receptor,

glucophorin A or  $\beta$ -HCG, a peptide subunit of any of the above, or a functional fragment of any of the above.

### ***Example 18***

#### ***Modification of Proteins Produced in Yeast***

A protein of interest, especially one described in Examples 15 and 17 is produced in a yeast selected from *Pichia spp* (especially *Pichia pastoris*), *Hansenula spp* (especially *Hansenula polymorpha*), *Kluyveromyces lactis*, *Yarrowia lipolytica*, or *S. cerevisiae* and treated as described in Example 12 with an  $\alpha$ -1,2 mannosidase prior to sequential treatment with GlcNAc Tr I,  $\beta$ -1,4 galactosyl transferase and  $\alpha$ 2,6-sialyl transferase.

Table 1

Datasheet: pCAMFhGNTIf1

Host/Plasmid Information

Storage No: 3124

Host Bacterium type: MC1061

Helper Plasmid:

Host/Plasmid Resistance: amp

Temperature: 37 °C

Additional Info:

Plasmid Description

CG: preMF $\alpha$ 1/hGlcNAc-TI (fusion of the prepro secretion signal sequence of the *S.cerevisiae*  $\alpha$ -mating factor 1 gene to the human cDNA fragment encoding mature N-acetylglucosaminyltransferase I)

SN: 3124

RU: Restricted Use

PG: EU-VARIA

SF: p3124.SEQ

DT:

LU:

<u>FT:</u>	Code	Start	Stop	Description	Comments
	LEN	6230U			LENGTH PLASMID
	CLO	1D	170D	rGIBf	PART EXON 3 + 3UTR + polyR OF RABBIT $\beta$ -GLOBIN
	CLO	171D	529D	3FR	3' FLANKING REGION OF RABBIT $\beta$ -GLOBIN GENE
	PRO	622D	605D	lac	PROMOTER
	ORI	747D	948D	SVORI	SV40 FRAGMENT, CONTAINING BIDIRECTIONAL ORI
	SIG	951D	1025D	polyA	polyA SIGNAL OF THE SV40 EARLY REGION
	SIG	1025D	951D	polyA	polyA SIGNAL OF THE SV40 LATE REGION
	ORI	1540U	1140U	ORI	ORIGIN PLASMID
	SEL	2943D	2083D	AMP	ANTIBIOTIC RESISTANCE GENE
	CLO	3093D	3460D	hCMV	hCMV-IE ENHANCER
	PRO	3472U	4705D	Ac	CHICKEN $\beta$ -ACTIN PROMOTER
	SIG	4721D	4975D	preMF	<i>S.cerevisiae</i> $\alpha$ -MATING FACTOR 1.PREPRO SEQ.

GEN 4976D 6190D GNTIf hGlcNAc-TI FRAGM. CONTAINING MATURE SEQ.

**HC:** E.coli

Mammalian cells (COS cells for transient expression; others for permanent transformation)

**IM:**

**OR:** Eco-pMB1

SV40

**PC:** pCAGGS; pSCGAL1MF3; pUCHGNTI1

**PR:** hCMV-IE (promoter enhancer)

CHI-Ac

Eco-lac

**RB:** Eco-lacZ

**RF:** Kumar et al., Proc. Natl. Acad. Sci. USA 87 (1990), 9948-9952

Marleen Maras and Roland Contreras

**RK:** Start of the nucleotide sequence in the middle of the EcoRI site.

This plasmid was made as follows: 1) The XbaI-StuI fragment of pSCGAL1MF3, containing the prepro secretion signal sequence of the *S.cerevisiae*  $\alpha$ -mating factor 1 gene, was ligated to the XbaI-Eco47III vector fragment of pUCHGNTI1; 2) This intermediate construction was then digested with HindIII and EcoRI, the sticky ends were filled in with Klenow DNA polymerase and EcoRI linkers (5'-CGGAATTCCG-3') were added; 3) Finally, this EcoRI-EcoRI fragment was digested with XbaI and EcoRI and the resulting XbaI-EcoRI fragment was inserted into the XbaI-EcoRI digested pCAGGS vector.

This expression plasmid carries a fusion of the prepro secretion signal sequence of the *S.cerevisiae*  $\alpha$ -mating factor 1 gene to the mature human gene encoding N-acetylglucosaminyltransferase I, cloned into the sense orientation relative to the chicken  $\beta$ -actin promoter which is preceded by the CMV-IE enhancer sequence.

The nucleotide sequence of the human GlcNAc-TI gene was obtained from the EMBL Nucleotide Sequence Database (Accession number M55621).

**RS:** U-AflII, U-AIwNI, U-ApaI, U-AvrII, U-BbsI, U-BcgI, U-BsaAI, U-Bsml, U-Bsp1201, U-DrdI, U-EcoRI, U-FspI, U-HindIII, U-MamI, U-MstII, U-NsiI, U-PflMI, U-PvuI, U-SfiI, U-SmaI, U-SnaBI, U-SnaI, U-SpeI, U-SphI, U-Sse8387I, U-Sspl, U-XbaI, U-XcmI, U-XmaI

**SE:** amp

**SQ:** /pCAGGS/13/4722/p2154/724/460/hGNTI/285/1505/TCGACTGGA/  
/pUC18/419/400/CGGAA//

**TE:**

**VS:** SHUTTLE

**SD:**

Table 2

Datasheet: pSCGAL1MF3

Host/Plasmid Information

Storage No: 3123  
 Host Bacterium type: MC1061  
 Helper Plasmid:  
 Host/Plasmid Resistance: amp  
 Temperature: 37 °C  
 Additional Info:

Plasmid Description

CG: preMF c1 (prepro secretion signal of the *S.cerevisiae*  $\alpha$ -mating factor 1 gene)

SN: 3123

RU: -

PG: YEAST

SF: p3123.SEQ

DT:

LU:

<u>FT:</u>	Code	Start	Stop	Description	Comments
	LEN	3477U			LENGTH PLASMID
	GEN	451D	238D	lacZ	lacZ $\alpha$ DNA
	SIG	716D	452D	preMF	<i>S.cerevisiae</i> $\alpha$ -MATING FACTOR 1 PREPRO SEQ.
	PRO	1211U	828D	GAL1	PROMOTER
	PRO	1362U	1299D	lac	PROMOTER
	ORI	1860U	1470U	ORI	ORIGIN PLASMID
	SEL	3277D	2417D	AMP	ANTIBIOTIC RESISTANCE GENE

HC: E.coli

IM:

OR: Eco-pMB1

PC: pSCGAL1MF2

PR: Sce-GAL1

Eco-lac

RP: Eco-lacZ



**RF:** Peter Impe and Roland Contreras

**RK:** Start of the nucleotide sequence between the ampicillin resistance gene and the lacZ DNA.  
This plasmid was made as follows: pSCGAL1MF2 was Accl opened, filled in with Klenow DNA polymerase and ligated. In this way the HindII and Sall sites of the polylinker are lost, an NruI site in the polylinker is created, and the HindII site in the prepro secretion signal of the *S.cerevisiae*  $\alpha$ -mating factor gene 1 becomes unique.  
U-MamI cut only in dam-negative strains.

**RS:** E-Asp718, E-BspMI, E-HindIII, E-KpnI, E-NruI, E-SphI, E-Sse8387I, E-StuI  
U-AatII, U-AflIII, U-AgeI, U-AlwNI, U-Asp700, U-BbeI, U-BcgI, U-BsaI, U-BspMII,  
U-Eam1105I, U-EcoO109, U-EheI, U-HindII, U-KasI, U-MamI, U-NarI, U-NdeI,  
U-PssI, U-ScaI, U-SspI

**SE:** amp

**SQ:** /p2154/1/432/p2154/431/3475//

**TE:**

**VS:** PLASMID

**SD:**

Table 3

Datasheet: pCAGGS

Host/Plasmid Information

Storage No: 2453  
 Host Bacterium type: MC1061  
 Helper Plasmid:  
 Host/Plasmid Resistance: amp  
 Temperature: 37 °C  
 Additional Info:

Plasmid DescriptionCG:SN: 2453RU: Restricted UsePG: EU-VARIASF: pCAGGS.SEQDT:LU:

<u>FT:</u>	Code	Start	Stop	Description	Comments
	LEN	4818U			LENGTH PLASMID
	CLO	10D	182D	rGIBf	PART EXON 3 + 3UTR + polyR OF RABBIT $\beta$ -GLOBIN
	CLO	183D	541D	3FR	3' FLANKING REGION OF RABBIT $\beta$ -GLOBIN GENE
	PRO	701U	618D	lac	PROMOTER
	ORI	859D	961D	SVORI	SV40 FRAGMENT, CONTAINING BIDIRECTIONAL ORI
	SIG	963D	1037D	polyA	polyA SIGNAL OF THE SV40 EARLY REGION
	SIG	1037D	963D	polyA	polyA SIGNAL OF THE SV40 LATE REGION
	ORI	1555U	1145U	ORI	ORIGIN PLASMID
	SEL	2955D	2095D	AMP	ANTIBIOTIC RESISTANCE GENE
	CLO	3095D	3472D	CMV	CMV-IE ENHANCER
	PRO	3464U	4818D	AG	$\beta$ -ACTIN/ $\beta$ -GLOBIN HYBRID PROMOTER: SEE RK

HC: E.COLI

Mammalian cells (COS-cells for transient expression; others for permanent transformation)

IM:

OR: Eco-pMB1  
SV40

PC: pUC13; pAGS-3 (neither of them is present in the physical stock)

PR: CHI/RAB-AG  
hCMV-IE (promoter enhancer)  
Eco-lac

RB: Eco-lacZ

RF: This plasmid was a gift from Prof. J. Miyazaki (University of Tokyo, Japan).  
Niwa et al., Gene 108 (1991), 193-200  
Peter Vanhoenacker

RK: Start of the nucleotide sequence in the middle of the non-unique EcoRI site.

The nucleotide sequence of the plasmid was reconstructed according to the information in the publication of Niwa et al., 1991. The following restriction sites were experimentally verified (Marc Van de Craen and Vera Goossens): BglII, BsaAI, HindII, MstII, NcoI, SspI, PvuII, XbaI and XhoI. This plasmid is useful for highly efficient expression of genes under the control of the chicken  $\beta$ -actin/rabbit  $\beta$ -globin hybrid promoter + CMV-IE enhancer in various mammalian cells. pCAGGS carries a modified chicken  $\beta$ -actin promoter: the splice acceptor sequence of the  $\beta$ -actin promoter region is replaced by a rabbit  $\beta$ -globin fragment containing a 3' part of the second intron and a 5' part of the third exon. The resulting  $\beta$ -actin/ $\beta$ -globin hybrid promoter is designated the AG promoter.

U-BclI cuts only in dam-negative strains.

RS: U-AccI, U-ApaI, U-Asp700, U-BalI, U-BcgI, U-BglII, U-BsaAI,  
U-BsaI, U-BsmI, U-Bsp120I, U-BstXI, U-DrdI, U-EagI, U-Eam1105I,  
U-EspI, U-FspI, U-HindII, U-HindIII, U-MstII, U-NsiI, U-PfIMl,  
U-PstI, U-PvuI, U-SacII, U-SalI, U-ScaI, U-SfaNI, U-SfiI,  
U-SgrAI, U-SnaBI, U-SpeI, U-SspI, U-StuI, U-XbaI, U-XhoI

SE: amp

SQ: /TTCCTCGAGGAA/RGlobinB/1545/2069/NNNNC'/pUC13/427/624/NNNNNNNNNNN'/  
/pAGS-3/350/4/N'/pUC13/625/2611/NNNNNGTC'/pCDM8/2815/2435/NNNNNGTC'/  
/pAGS-3/2998/1664//

TE:

VS: SHUTTLE

SP:

65

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT:
- (ii) TITLE OF INVENTION: Methods of Modifying Carbohydrate Moieties
- (iii) NUMBER OF SEQUENCES: 5
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE:
  - (B) STREET:
  - (C) CITY:
  - (D) STATE:
  - (E) COUNTRY:
  - (F) ZIP:
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME:
  - (B) REGISTRATION NUMBER:
  - (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE:
  - (B) TELEFAX:

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 26 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: not relevant
- (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CCAGGATGCT GAAGAAGCAG TCTGCA

66

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 28 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCAGTCCACA GGTGCTAATT CCAGCTAG

28

## (2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 41 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Leu	Lys	Lys	Gln	Ser	Ala	Gly	Leu	Val	Leu	Trp	Gly	Ala	Ile	Leu
1				5				10					15		

Phe	Val	Ala	Trp	Asn	Ala	Leu	Leu	Leu	Leu	Phe	Phe	Trp	Thr	Arg	Pro
			20					25					30		

Ala	Pro	Gly	Arg	Pro	Pro	Ser	Val	Ser
			35				40	

## (2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 255 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: not relevant
  - (D) TOPOLOGY: not relevant

(ii) MOLECULE TYPE: peptide

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..255

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATG AGA TTT CCT TCA ATT TTT ACT GCA GTT TTA TTC GCA GCA TCC TCC	48
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser	
1 5 10 15	
GCA TTA GCT GCT CCA GTC AAC ACT ACA ACA GAA GAT GAA ACG GCA CAA	96
Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln	
20 25 30	
ATT CCG GCT GAA GCT GTC ATC GGT TAC TCA GAT TTA GAA CGG GAT TTC	144
Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe	
35 40 45	
GAT GTT GCT GTT TTG CCA TTT TCC AAC AGC ACA AAT AAC GGG TTA TTG	192
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu	
50 55 60	
TTT ATA AAT ACT ACT ATT GCC AGC ATT GCT GCT AAA GAA GAA GGG GTA	240
Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val	
65 70 75 80	
TCT TTG GAT AAA AGG	255
Ser Leu Asp Lys Arg	
85	

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 85 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu Phe Ala Ala Ser Ser	
1 5 10 15	
Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln	
20 25 30	
Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp Phe	
35 40 45	
Asp Val Ala Val Leu Pro Phe Ser Asn Ser Thr Asn Asn Gly Leu Leu	
50 55 60	
Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val	
65 70 75 80	
Ser Leu Asp Lys Arg	
85	

***What Is Claimed Is:***

1. A process for producing a hybrid glycoprotein, said method comprising:
  - (a) culturing filamentous fungi so as to produce a high mannose type glycoprotein that is an acceptor substrate for GlcNAc Tr I;
  - (b) reacting said glycoprotein with GlcNAc Tr I;
  - (c) reacting the glycoprotein product of step (b) with  $\beta$ -1,4 galactosyl transferase;
  - (d) reacting the glycoprotein product of step (c) with  $\alpha$ -2,6-sialyltransferase.
2. The process of claim 1, wherein said glycoprotein is a protein that is homologous to said fungi.
3. The process of claim 1, wherein said glycoprotein is a protein that is heterologous to said fungi.
4. The process of claim 1, wherein said fungi is a *Trichoderma*.
5. The process of claim 4, wherein said *Trichoderma* is *Trichoderma reesei*.
6. The process of any one of claims 1-5, wherein step (b) occurs intracellularly in said host, and steps (c) and (d) are performed *in vitro*.
7. The process of any one of claims 1-5, wherein steps (b), (c) and (d) are performed *in vitro*.
8. The process of claim 7, wherein said glycoprotein is reacted with  $\alpha$ -1,2 mannosidase between steps (a) and (b).
9. A process for producing a hybrid glycoprotein, said method comprising:
  - (a) reacting a high mannose type glycoprotein with an  $\alpha$ -1,2-mannosidase;
  - (b) reacting the glycoprotein product of step (a) with GlcNAc Tr I;
  - (c) reacting the glycoprotein product of step (b) with  $\beta$ -1,4 galactosyl transferase;
  - (d) reacting the glycoprotein product of step (c) with  $\alpha$ -2,6-sialyltransferase.

10. The process of claim 9, wherein step (a) occurs intracellularly in a fungus expressing said high mannose type glycoprotein and expressing said  $\alpha$ -1,2-mannosidase; and further wherein steps (b), (c), and (d) are performed *in vitro*.

11. The process of claim 9, wherein steps (a) and (b) occur intracellularly in a fungus expressing said high mannose type glycoprotein, said  $\alpha$ -1,2-mannosidase, and said GlcNAc Tr I; and further wherein steps (c) and (d) are performed *in vitro*.

12. The process of claims 9-11, wherein said high mannose glycoprotein was produced in a yeast.

13. The process of claim 12, wherein said yeast is selected from the group consisting of a member of the *Pichia spp.*, *Hansenula spp.*, *Kluyveromyces lactis*, *S. cerevisiae*, and *Yarrowia lipolytica*.

14. The process of claim 13, wherein said *Pichia spp.* is *Pichia pastoris*.

15. The process of claim 13, wherein *Hansenula spp.* is *Hansenula polymorpha*.


16. The process of claim 13, wherein said yeast is *S. cerevisiae*.

17. The process of claims 9-11, wherein said high mannose glycoprotein was produced in filamentous fungi.

18. The process of claim 17, wherein said fungi is a *Trichoderma*.

19. The process of claim 18, wherein said *Trichoderma* is *Trichoderma reesei*.





**FIG. 1**

2/17




FIG. 1A

3/17




FIG. 2

pCAGGS

4/17



pSCGAL1MF3

FIG. 3

5/17




FIG. 4

pCAMFhGNT1f1

6/17




FIG. 4A

7/17




FIG. 4B

8/17





FIG. 4C



9/17



10/17




FIG 5

11/17




FIG 6

12/17




FIG 7

13/17



FIG 8

14/17




FIG 9

15/17




FIG 10

16/17




FIG 11



17/17




FIG 12

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 96/00002

## A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12P 19/28, C12P 1/00, C12P 19/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, CA, BIOSIS, WPIDS, USPATFULL

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5272066 A (MICHEL L. F. BERGH ET AL), 21 December 1993 (21.12.93) --	1-19
A	US 5324663 A (JOHN B. LOWE), 28 June 1994 (28.06.94) --	1-19
A	US 4770994 A (HARRY G. RITTENHOUSE), 13 Sept 1988 (13.09.88) --	1-19



Further documents are listed in the continuation of Box C.



See patent family annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*B\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Δ\* document member of the same patent family

Date of the actual completion of the international search

3 April 1996

Date of mailing of the international search report

10 -04- 1996

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Carolina Gómez Lagerlöf  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI 96/00002

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Liebigs Ann. 1995, H. Paulsen et al: "Synthese von modifizierten Oligosacchariden der N-Glycoproteine zur Untersuchung der Substratspezifität der N-Acetylglucosaminyltransferase I", see page 53-66</p> <p style="text-align: center;">-- -----</p>	1-19

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

05/02/96

International application No.  
PCT/FI 96/00002

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US-A-	5272066	21/12/93	US-A- 4925796	15/05/90
US-A-	5324663	28/06/94	AU-A- 4774793	14/02/94
			CA-A- 2140550	03/02/94
			EP-A- 0654082	24/05/95
			WO-A- 9402616	03/02/94
			ZA-A- 9305237	18/03/94
			CA-A- 2075949	15/08/91
			EP-A, A- 0515536	02/12/92
			JP-T- 5504480	15/07/93
			WO-A- 9112340	22/08/91
US-A-	4770994	13/09/88	CA-A- 1236090	03/05/88
			JP-C- 1812224	27/12/93
			JP-B- 5023760	05/04/93
			JP-A- 59059200	04/04/84